Cardiovascular Medicine and Haematology articles for United States of America (USA)

Time frame: 1 June 2025 - 30 May 2026

View topic

Count: 902

Article ‘Count’ for Cardiovascular Medicine and Haematology.

Journal Count Share
3 1.26
Force-Induced Ankle Opening Reveals Mechanical Stabilization of the Ankle of Human β-Cardiac Myosin 1.00
Lung-Accumulating Mucin 5AC Silencing by Noninflammatory Lipid Nanoparticles for Asthma Treatment 0.05
Reprogramming Lesional Macrophage Homeostasis via Interferon Regulatory Factor 5 Targeted siRNA Nanoimmunotherapy for Atherosclerosis 0.21
11 9.48
Valve endothelial monolayer fissuring and interstitial matrix fracture triggers calcific lesion formation via GTPase signaling 1.00
Lung tissue viscoelasticity is preserved with bleomycin-induced fibrosis in mice 1.00
A Unified Finite Element Framework for Cardiac Growth and Remodeling in Mitral Regurgitation Incorporating Fiber Reorientation and Baroreflex 1.00
Artificial intelligence-assisted multiscale lung modeling to predict alveolar septal wall stress 1.00
Calcification and Structural Damage Together Accelerate Porcine Pericardium Failure 0.43
The ICE-AFIB trial: A multicenter prospective investigational device exemption (IDE) trial using cryosurgical ablation for atrial fibrillation during concomitant cardiac surgery 1.00
Comparative biomechanical and structural evaluation of region-specific stented and non-stented ex vivo perfused human thoracic aortas 0.06
Biomaterial-based 3D human lung models replicate pathological characteristics of early pulmonary fibrosis 1.00
Dissection Propagation via Avalanches in Human Descending Thoracic Aorta: Effect of Aging 1.00
Advanced tissue-engineered pulsatile conduit using human induced pluripotent stem cell-derived cardiomyocytes 0.99
Sex- and region-specific differences in microstructural remodeling and passive biomechanics of the aorta correlate with aneurysm propensity in a mouse model of severe Marfan syndrome 1.00
1 1.00
A Vascular Microphysiological Model of Lung Fibrosis Reveals That Myofibroblasts and IPF Patient‐Derived Fibroblasts Impair Angiogenesis and Vasculogenesis 1.00
2 2.00
The influence of hemoglobin measurement error on accuracy of population anemia surveillance: results from mathematical simulations 1.00
Gut microbiota-derived pro-inflammatory biomarkers and risk of coronary artery disease: a prospective study among US men and women 1.00
4 4.00
Neighborhood-level socioeconomic position and mortality among children born with critical congenital heart defects 1.00
The effects of a smoking cessation intervention on mortality after a 32.5-year follow-up period: a randomized clinical trial 1.00
Obstructive sleep apnea and functional hearing loss over 8 years: results from the National Health and Aging Trends Study 1.00
Use of censored data methods to estimate blood pressure percentiles in US adults 1.00
4 4.00
PPARα Deficiency Induces Vascular Pathologies through Endothelial Senescence in Diabetic Retinopathy 1.00
Specialized pro-resolving mediators MaR1 and LXA4 resolve inflammation during acute chemical lung injury in the absence of neutrophils 1.00
Endothelial cell STING regulates IL6 production and is required for pathological cardiac hypertrophy and contractile dysfunction in experimental heart failure 1.00
Macrophage-KLF6 signaling promotes experimental atherogenesis. 1.00
49 32.22
Tezepelumab in Real-World U.S. Patients with Severe Asthma Across Phenotypes and Underrepresented Populations: The Phase 4 PASSAGE Study 0.90
Astegolimab for COPD With Frequent Exacerbations: Pooled Analysis of the ALIENTO and ARNASA Trials 0.35
Single-cell Sequencing Unveils A Profibrotic Macrophage and Infiltrating Monocyte Niche in the Bronchoalveolar Lavage of Patients with Chronic Obstructive Pulmonary Disease 0.20
Aroxybutynin and atomoxetine (AD109) for obstructive sleep apnea: a randomized phase 3 trial (SynAIRgy) 1.00
Dupilumab in COPD: A Pooled Analysis of Emergency Department Visits, Hospital Admissions, and Systemic Corticosteroid Use 0.50
Post-Tuberculosis Lung Disease in Treated Extra-Pulmonary Tuberculosis 0.33
Effectiveness of automatically-adjusted vs manually-adjusted noninvasive ventilation in obesity hypoventilation syndrome: a randomized clinical trial 0.04
Nerandomilast in idiopathic pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-IPF trial 0.46
Sub-phenotypes of pneumonia defined by pulmonary histopathological features 1.00
Idiopathic Pulmonary Fibrosis Risk Loci in East Asian Populations Mirror those of European Populations 0.36
Deupirfenidone Compared with Pirfenidone and Placebo in Idiopathic Pulmonary Fibrosis (ELEVATE-IPF): a Phase 2b Randomized Placebo-Controlled Trial 0.61
Molecular endotypes predict differential response to immunosuppressant therapy in non–idiopathic pulmonary fibrosis interstitial lung disease 1.00
Phase 2b trial of inhaled imatinib for treatment of pulmonary arterial hypertension 0.52
Mosaic Loss of Y chromosome associates with lung function, emphysema and epigenetic aging 1.00
Discriminative Performance and Clinical utility of COPD Exacerbation Categories for Predicting Future Exacerbations 0.67
CES1 Deficiency is Associated With Metabolic Reprograming and Endothelial Dysfunction in Pulmonary Arterial Hypertension 1.00
Pulmonary Rehabilitation is Associated with Increased 1-Year Survival in Stable COPD 1.00
Clinical and transcriptomic risk factors for post-tuberculosis lung disease in a cohort of Kenyan adults 0.69
The Long-term Pneumonia Mortality Index. An International Multicenter Derivation and Validation Study for Patients with Community-Acquired Pneumonia 0.20
Motivational Interviewing and Air Cleaners for Smokers with COPD (MOVE): A Randomized, Double-Blind, Placebo-Controlled Trial 1.00
Mucus plugs in chronic obstructive pulmonary disease are heterogeneous in size and shape and occur in relatively large airways 1.00
Effect of Dupilumab on Mucus Burden in Patients with Moderate-to-Severe Asthma: The VESTIGE Trial. 0.50
Mucus Plugs-associated Gene Expression Identifies Pathophysiology Shared with Chronic Bronchitis. 1.00
Airway Epithelial Heterogeneity and Mucus Plugging in Asthmatic Bronchioles. 1.00
Randomized Sham Controlled Trial of Targeted Lung Denervation in Patients with COPD (AIRFLOW-3). 0.43
Associations of High Attenuation Area-related Proteomic Biomarkers with Fibrotic or Subpleural Interstitial Lung Abnormalities. 1.00
Mucus Plugs Correlate with Small Airway Remodelling in Asthma: A Case-Control Study. 0.33
One-Year Change in Quantitative Computed Tomography Is Associated with Meaningful Outcomes in Fibrotic Lung Disease. 0.92
Active Antigen-Specific Adaptive Immune Responses Are Shared among Patients with Progressive Fibrotic Interstitial Lung Disease. 1.00
Ionocyte CFTR Coordinates Chloride Absorption and Secretion to Balance Airway Fluid. 1.00
Impact of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance and Abnormal Glucose Metabolism: A Phase 3b, Open-Label Clinical Trial. 0.44
Impact of Sleep Apnea on Perivascular Diffusivity and Cognition: A 4-Year Prospective Cohort Study. 0.08
Inflammation and Obesity Correlate in Pulmonary Hypertension but Associate with Diverging Outcomes. 0.07
Hemodynamics and Phosphodiesterase-5 Inhibitor Treatment Associated with Survival in ILD-PH: A PVRI GoDeep Meta-Registry Analysis. 0.27
Proteomic Biomarkers of Survival in Non–Idiopathic Pulmonary Fibrosis Interstitial Lung Disease 1.00
Visual and Quantitative Interstitial Lung Abnormality Progression in COPDGene. 0.94
A Quantitative Imaging Measure of Progressive Pulmonary Fibrosis. 1.00
Molecular Phenotyping of Sepsis and Differential Response to Fluid Resuscitation. 1.00
The Plasma Proteome in Community-acquired Pneumonia: Pathophysiology, Outcome and 10-Year Risk. 0.07
Deep Learning Estimation of Small Airway Disease from Inspiratory Chest Computed Tomography: Clinical Validation, Repeatability, and Associations with Adverse Clinical Outcomes in Chronic Obstructive Pulmonary Disease 1.00
Lipid Ratios for Diagnosis and Prognosis of Pulmonary Hypertension 0.10
Associations of Prepandemic Lung Function and Structure with COVID-19 Outcomes: The C4R Study 0.98
Dual αvβ6 and αvβ1 Inhibition over 12 Weeks Reduces Active Type I Collagen Deposition in Individuals with Idiopathic Pulmonary Fibrosis: A Phase 2, Double-Blind, Placebo-controlled Clinical Trial 1.00
Performance Characteristics for Physiological Measures of Progressive Pulmonary Fibrosis. 0.58
Deficient FANCL Predisposes Endothelial Damage: A New Therapeutic Target for Pulmonary Hypertension. 0.10
Metabolomic Evidence of Biological Overlap with HFpEF in a Subset of Pulmonary Arterial Hypertension. 1.00
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children ≥6 Years with Cystic Fibrosis and at Least One F508del Allele: A 192-Week, Phase 3, Open-Label Extension Study. 0.56
Camlipixant in Refractory Chronic Cough: A Phase 2b, Randomized, Placebo-controlled Trial (SOOTHE) 0.50
<atl>Consistent Safety and Efficacy of Sotatercept for Pulmonary Arterial Hypertension in iBMPR2/i Mutation Carriers and Noncarriers: A Planned Analysis of a Phase II, Double-Blind, Placebo-controlled Clinical Trial (PULSAR)</atl> 0.53
3 1.77
Microsensor Array for the Electrochemical Analysis of Hydroxyurea in Blood Samples of Children Affected by Sickle Cell Anemia 0.33
A QCM-Based Biosensor to Detect HIT-like Antibodies: Differentiating KKO from RTO via FcγRIIA Interactions 0.44
Detection and Analysis of Reactive Oxygen Species (ROS): Buffer Components Are Not Bystanders 1.00
3 2.85
Intraoperative Cardiac Events in Pediatric Patients with Congenital Heart Disease Undergoing Noncardiac Procedures: Analysis of a Large Multicenter Registry. 0.89
TEG® 6s heparin neutralization cartridge for hemostatic assessment of patients undergoing cardiovascular surgery. 0.96
Transfusion of Amustaline/Glutathione Pathogen-Reduced Red Blood Cells in Cardiac Surgery - A Randomized Phase III Clinical Trial 1.00
3 3.00
Dexamethasone Treatment Regimen and Clinical Outcomes in Children With Asthma Exacerbations 1.00
Opportunistic Screening for Atrial Fibrillation With Continuous ECG Monitoring in the Emergency Department 1.00
Incidence and Clinical Relevance of Echocardiographic Visualization of Occult Ventricular Fibrillation: A Multicenter Prospective Study of Patients Presenting to the Emergency Department After Out-of-Hospital Cardiac Arrest 1.00
6 4.96
Proximal Hypoglossal Nerve Stimulation for Obstructive Sleep Apnea in the OSPREY Study : A Randomized Controlled Trial. 0.82
Short Versus Longer Antibiotic Duration for Community-Acquired Pneumonia : A Multicenter Target Trial Emulation. 1.00
The Risk for Bleeding in Patients With Atrial Fibrillation From Concomitant Use of Apixaban or Rivaroxaban With Diltiazem Compared With Metoprolol. 1.00
Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists on Diabetic Foot Disease : An Emulated Target Trial. 0.14
Effect of Systolic Blood Pressure Measurement Error on the Cost-Effectiveness of Intensive Blood Pressure Targets. 1.00
Comparison of Semaglutide or Dulaglutide Versus Empagliflozin for Risk for Death and Cardiovascular Outcomes Among Patients With Type 2 Diabetes : Two Target Trial Emulation Studies. 1.00
3 2.49
Apixaban Versus Aspirin and Risk of Hemorrhage in the ARCADIA Trial 0.87
<atl>Prospective, Multicenter Evaluation of Transcarotid Artery Revascularization in Standard‐Risk Patients: 30‐Day Outcomes of the scpROADSTER/scp 3 Study</atl> 1.00
Carotid Revascularization Versus Medical Management for Ischemic Stroke with Ipsilateral Carotid Web: A Systematic Review and Meta‐Analysis 0.63
6 5.06
“Textbook Outcome” in Endovascular Aortic Repair is Associated With Improved One-year Survival 1.00
A Frozen Elephant Trunk Technique to Reduce Circulatory Arrest Time in Hybrid Aortic Arch for Acute Aortic Dissection: Early and Midterm Outcomes in a Multicentric Cohort of 153 Patients. 0.06
Randomized Controlled Trial of New Oral Anticoagulants Versus Warfarin for Post Cardiac Surgery Atrial Fibrillation: The NEWAF Trial. 1.00
Transcarotid Artery Revascularization Versus Carotid Endarterectomy With and Without High-Risk Criteria: A National Target Trial. 1.00
C-C Chemokine Receptor 2 is a Tissue Biomarker for Abdominal Aortic Aneurysmal and Occlusive Disease. 1.00
Vascular Calcification Amplifies Limb Flexion-Induced Arterial Deformations and Causes Intermittent Vessel Pinching. 1.00
4 2.89
Altered AP-1, RUNX, and EGR chromatin dynamics drive human fibrotic lung disease 0.97
Use of statins and its association with major adverse cardiovascular events with tofacitinib vs TNF inhibitors in patients with rheumatoid arthritis with and without atherosclerotic cardiovascular disease 0.63
Two-year efficacy and safety of anti-interleukin-5/receptor therapy for eosinophilic granulomatosis with polyangiitis 0.30
Disease Trajectories and Glucocorticoid Exposure in VEXAS Syndrome Treated with Cytokine-Directed Therapies 1.00
1 1.00
Non-cardiac Pain Prevalence, Pain Intensity, Pain Interference, Sleep, and Cardiopulmonary Function in Outpatient Cardiac Rehabilitation 1.00
9 6.78
Impact of Evolving Treatment Patterns on Interstitial Lung Disease Progression in Systemic Sclerosis Using the European Scleroderma Trials and Research Database 0.06
Performance of the Predicting Risk of Cardiovascular Disease Events Calculator in Rheumatoid Arthritis 1.00
Single‐Cell Analysis Reveals Peripheral Helper T Cells in Rheumatoid Arthritis–Related Interstitial Lung Disease 1.00
Glucagon‐Like Peptide‐1 Receptor Agonist Use and the Risk of Adverse Cardiac and Kidney Outcomes Among Patients with Systemic Lupus Erythematosus and Lupus Nephritis 1.00
The Effect of Benralizumab and Mepolizumab on Use of Oral Glucocorticoids in Patients with Eosinophilic Granulomatosis with Polyangiitis 0.27
Performance of an Idiopathic Pulmonary Fibrosis Derived Multibiomarker Panel for Rheumatoid Arthritis‐Associated Interstitial Lung Disease 1.00
Long‐Term Safety and Efficacy of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis 0.75
Comparative Cardiovascular Safety of Nonsteroidal Anti‐Inflammatory Drug Versus Colchicine Use When Initiating Urate‐Lowering Therapy Among Patients With Gout: Target Trial Emulations 0.70
Clinical manifestations of scpVEXAS/scp syndrome across a broad spectrum of scpUBA1/scp mutation burden 1.00
17 11.57
Evolution of tumor subclones and T-cell dynamics underlie variable ibrutinib responses in Waldenström macroglobulinemia 0.87
An optimized CRISPR-Cas12a genome-wide screen reveals PTPA phosphatase pathway in fetal hemoglobin silencing 0.95
Treatment-related outcomes and patterns of relapse in secondary CNS involvement by large B-cell lymphoma 0.66
A decade of ibrutinib for CLL with and without TP53 aberration: final report on an investigator-sponsored phase 2 study 1.00
Heme-induced activation of the TLR3/TRIF–IFN-I–CCL2 pathway contributes to kidney injury in sickle cell disease 1.00
The landscape and evolution of clonal hematopoiesis in chronic lymphocytic leukemia 0.11
PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study 0.53
TNFα signaling restores steady-state hematopoiesis in a TNFαKO mouse model of anemia of inflammation 0.88
Modeling the HLH immune synapse uncovers critical roles for IS termination, cytokine intensity, and target cell death 1.00
TCA cycle mode switch determines the fate of pirtobrutinib-tolerant persister cells in mantle cell lymphoma 1.00
Clinical phenotype and pathophysiological mechanisms underlying qualitative low VWF 0.04
Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab 1.00
Rapid ADAMTS13 activity assays for thrombotic thrombocytopenic purpura: a systematic review and meta-analysis 1.00
A controlled trial for preventing priapism in sickle cell anemia: hydroxyurea plus placebo vs hydroxyurea plus tadalafil 0.16
Destabilization of PF4-antigenic complexes in heparin-induced thrombocytopenia 0.69
Synergistic antitumor effect of combined EZH2 and DOT1L inhibition in B-cell lymphoma 0.46
The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLL 0.23
3 1.36
Development of a standard definition of ‘no-option’ and ‘poor-option’ for revascularization in chronic limb-threatening ischemia 0.30
<atl>Open surgery iversus/i branched endovascular repair of the aortic arch in residual dissections after type A surgical repair</atl> 0.06
A comparison of women and men with small abdominal aortic aneurysms 1.00
2 1.90
Axes of biological variation in diffuse large B cell lymphoma 0.90
Large B cell lymphoma microenvironment archetype profiles 1.00
2 2.00
A triple-node heart-brain neuroimmune loop underlying myocardial infarction 1.00
Renal PIEZO2 is an essential regulator of renin 1.00
2 1.30
An infant nasal microbial gene atlas uncovers intervention-driven microbiome shifts and salt-resistant pathogen expansion 0.38
Pseudomonas infections persisting after CFTR modulators are widespread throughout the lungs and drive lung inflammation 0.92
2 1.01
NAD-dependent redox control enables endothelial quiescence and vascular stabilization during angiogenesis 1.00
Deletion of Mfn2 in endothelial cells triggers a mitohormetic response that improves systemic metabolism and healthspan in mice 0.01
1 0.94
Modulation of heme peroxo nucleophilicities with axial ligands reveal key insights into the mechanistic landscape of nitric oxide synthase 0.94
36 24.32
Three-Year Outcomes of Proximal Hypoglossal Nerve Stimulation in OSA 0.83
Imaging-based Pulmonary Hypertension Phenotypes in Connective Tissue Disease-related Interstitial Lung Disease 1.00
The Impact of Disease Severity and Symptoms on Anxiety and Depression in Individuals With Idiopathic Pulmonary Fibrosis 0.07
Association of Inhaling Marijuana With Asthma Attacks 1.00
The Epidemiology of Cryptogenic Organizing Pneumonia 1.00
Matrix Metalloproteinase 12 Improves the Differentiation of Idiopathic Pulmonary Fibrosis and Fibrotic Hypersensitivity Pneumonitis and Associates With Antigen Response Pathways 1.00
The Minimal Important Difference in N-Terminal Pro-Brain Natriuretic Peptide in Pulmonary Hypertension 1.00
Demographic and Physiological Differences Between Fibrotic and Nonfibrotic CT Subtypes of Sarcoidosis 0.84
A Randomized, Placebo-Controlled, Double-Blind, Crossover Trial of Inhaled Nitric Oxide in Patients With Mild-to-Severe COPD 0.04
Sex does not modify prediction of asthma attacks by clinical risk factors and Type-2 biomarkers 0.24
Formation and Growth of a Bronchiectasis and Pulmonary NTM Multidisciplinary Program Using a Patient-Centered and Integrated Care Model Improves Outcomes 1.00
Efficacy of Anti-Inflammatory Therapies for Adults with Non-Cystic Fibrosis Bronchiectasis: A Systematic Review and Network Meta-Analysis 0.67
The Influence of Heart Failure and Ventilatory Support mode on hospital morbidity and mortality in patients with or at risk for Obesity Hypoventilation syndrome: findings from the National Inpatient Sample 1.00
Recovery rate from exertional desaturation is associated with disease progression and mortality risk in patients with fibrotic interstitial lung disease 0.45
From Pulse to Phenotype: Sleep Apnea Endotyping for Polygraphy via Oximeter-derived Autonomic Arousal 0.20
Incidence of new comorbidities after steroid use in patients with sarcoidosis: an international cross-sectional survey 0.43
Treatment patterns in incident pulmonary hypertension patients: real-world data from the Pulmonary Hypertension Association Registry 1.00
Initial Evaluation of the Pulmonary Hypertension Functional Classification Self-Report (PH-FC-SR) Measurement Properties: A Patient-Focused Measure 0.70
Clinician Views on Inhaler Substitution in the Veterans Health Administration 1.00
Structural and functional pulmonary MRI to predict pulmonary exacerbations in Cystic Fibrosis 0.80
Cardiovascular Events in COPD: Complementary Role of Cardiac Risk and Coronary Artery Calcium Scores 0.23
Comparative outcomes and side effects of immunosuppressants and tumor necrosis factor inhibitors in sarcoidosis: a real-world data analysis 0.50
Clinical Validation of a Multidimensional Diagnostic Approach for Chronic Obstructive Pulmonary Disease in Chinese 0.04
Differential effects of antifibrotic treatment on outcome prediction via serial CRPM levels in IPF 0.02
Acetazolamide plus Atomoxetine for Obesity Hypoventilation Syndrome Treatment A Randomized Controlled Trial 0.18
Lung Function Changes Across the Menopausal Transition: A Longitudinal Analysis of Annual Exams 0.26
Inter-session Variability in Single-Breath Diffusing Capacity of Carbon Monoxide 1.00
Association between betel quid consumption and respiratory disease mortality in a prospective Bangladeshi cohort 0.50
An inventory of clinical sarcoidosis status in the United States 0.81
Procedure Patterns and Survival in Advanced Non-Small Cell Lung Cancer with Malignant Airway Obstruction: A SEER-Medicare Analysis 1.00
Intermittent Asthma and Risk of Severe Exacerbation in Children 1.00
Artificial Intelligence-Based Echocardiography in Pulmonary Arterial Hypertension 0.79
Hypoxic Burden is Associated with Cardiovascular Events: A Risk Stratification Analysis of the RICCADSA Cohort 0.90
The Impact of the Unknown: Patient Experiences with Uncertainty in Sarcoidosis 1.00
Airway Mucus Plugging in Chronic Bronchitis and the Impact of Bronchial Rheoplasty 0.86
Anti-Ro52 Seropositive Interstitial Lung Disease is Associated with a Higher Risk for Disease Progression and Mortality 0.94
70 40.24
A Genome-First Study of Familial Hypercholesterolemia Comparing African and European Ancestry Individuals 1.00
Integrative Molecular Analyses of Inflammatory and Autoimmune Signals in Cardiac Sarcoidosis 0.80
Hypoxia Upregulation of BACH1 Aggravates Pulmonary Hypertension Through TGFBR2/SMAD Pathways 0.07
Pulsed Field Ablation Versus Sham to Treat Atrial Fibrillation: The PFA-SHAM Randomized Clinical Trial 0.05
Lipoprotein(a) Levels, Risk of Cardiovascular Events, and Benefit of Evolocumab: Findings From the VESALIUS-CV Trial 0.50
Evolocumab in Patients With Prior Percutaneous Coronary Intervention and No Prior Myocardial Infarction: Results From the VESALIUS-CV Trial 0.43
Laroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for the Treatment of Hypercholesterolemia: Results From a Randomized, Single-Blind, Placebo-Controlled Phase 1 Trial in Treatment-Naïve Patients 0.28
Determining the Physiological Threshold for Angina (ORBITA-FIRE): A Double-Blind, Randomized, Placebo-Controlled Study. 0.03
JNK2 Is a Stress Integrator Driving Atrial Fibrillation Pathogenesis in Aging via Gut-Heart Crosstalk. 1.00
The Natural History of Massive Left Ventricular Hypertrophy in Pediatric Hypertrophic Cardiomyopathy: A Multiregistry Analysis. 0.47
Phone-Based Intervention Under Nurse Guidance for Control of Hypertension After Stroke: A Randomized Multicenter Phase 3 Trial in Ghana. 0.07
Cardiovascular-Kidney-Metabolic Syndrome Stages, Echocardiographic Characteristics, and Heart Failure Risk: The Atherosclerosis Risk in Communities Study. 0.85
The Fontan Outcomes Network: Findings After 2 Years and 1121 Participants. 0.95
A Critical Contribution of Cardiac Myofibroblasts in Right Ventricular Failure and the Role of UCP2 SNPs in the Predisposition to RV Decompensation in Pulmonary Arterial Hypertension. 0.15
Differences in Disease Trajectory, Comorbidities, and Mortality in Sarcomeric and Nonsarcomeric Hypertrophic Cardiomyopathy. 0.59
Small Extracellular Vesicle External Surface Adiponectin-Mediated Adipocytes/Cardiomyocytes Communication in Diabetic Ischemic Heart Failure. 1.00
Risk of Heart Failure Hospitalization for GLP-1 Receptor Agonists Versus DPP-4 Inhibitors or SGLT-2 Inhibitors in Patients With Type 2 Diabetes: A Target Trial Emulation. 0.14
Elevated Pulmonary Artery Wedge Pressure in Group 1 Pulmonary Hypertension. 1.00
Prospective Associations of Obesity and Obesity Severity With 9 Cardiovascular Outcomes: The Cross-Cohort Collaboration. 0.91
Natural History of Patients With Histologically Proven Acute Eosinophilic Myocarditis. 0.14
Defining an Optimal Result of Transcatheter Tricuspid Valve Intervention: Results From the Tri-QOL Study 1.00
Systemic Embolic Events in Atrial Fibrillation: An Individual Patient Data Meta-analysis of 71 683 Participants Randomized to NOAC Versus Warfarin. 0.77
Association of Pre-Fontan Hemodynamics With Long-Term Outcomes After Fontan Palliation: A Study From the Pediatric Cardiac Care Consortium 1.00
CXCR6+ T Cells Drive Immune Checkpoint Inhibitor Myocarditis. 0.88
Myocardial Recovery With Mechanical Circulatory Support Is Linked to Alternative Splicing and Subcellular Localization of CAMK2D. 1.00
Endothelial Transcription Factor EB Protects Against Doxorubicin-Induced Endothelial Toxicity and Cardiac Dysfunction. 1.00
IMPROVE-DiCE, a 2-Part, Open-Label, Phase 2a Trial Evaluating the Safety and Effectiveness of Ninerafaxstat in Patients With Cardiometabolic Syndromes. 0.30
Oxidized Phospholipids, Lipoprotein(a), and Cardiovascular Outcomes After Acute Coronary Syndrome 0.57
Leveraging a Genetic Proxy to Investigate the Effects of Lifelong Cardiac Sodium Channel Blockade. 0.40
OxLDL-Targeted Chimeric Antigen Receptor T Regulatory Cells Reduce Atherosclerotic Plaque Development. 1.00
Sacubitril-Valsartan for the Prevention of Anthracycline Cardiotoxicity in Patients With Elevated Cardiac Troponin I Concentration During Chemotherapy: A Double-Blind Randomized Placebo-Controlled Clinical Trial: The SARAH Trial. 0.06
Quantitative Identification of High-Risk Tricuspid Regurgitation by Cardiac Magnetic Resonance. 0.66
Cardiac Allograft Vasculopathy Inhibition with Alirocumab: The CAVIAR Trial. 0.94
Dapagliflozin to Reduce Early Recurrence After Catheter Ablation for Atrial Fibrillation: The DARE-AF Randomized Clinical Trial. 0.07
Incidence, Risk Factors, and Outcomes in Stressor-Associated Atrial Fibrillation: Insights from the VITAL-AF Trial 0.98
Deep Learning–Based Continuous QT Monitoring to Identify High-Risk Prolongation Events After Class III Antiarrhythmic Initiation 1.00
Efficacy and Safety of Very Low Achieved LDL-Cholesterol in Patients with Prior Ischemic Stroke. 0.69
Geometric Features of Ventricular Tachycardia Corridors in Patients With Ischemic Cardiomyopathy. 0.95
IRF5 siRNA Nanoimmunotherapy: Restoring Macrophage Efferocytosis in Atherosclerosis. 0.25
The Role of the Collateral Circulation in Stable Angina: An Invasive Placebo-Controlled Study. 0.03
Bailout Intracranial Angioplasty or Stenting After Thrombectomy for Acute Large Vessel Occlusion: 1-Year Outcomes of ANGEL-REBOOT. 0.02
Heart Stress and Blood Pressure Management in Older Adults: Post Hoc Analysis of the ASPREE Trial. 0.14
Hypercontractility and Oxidative Stress Drive Creatine Kinase Dysfunction in Hypertrophic Cardiomyopathy. 0.03
High-Voltage Focal Pulsed Field Ablation to Treat Scar-Related Ventricular Tachycardia: The First-in-Human VCAS Trial. 0.40
Single-Cell Splicing Isoform Atlas of the Adult Human Heart and Heart Failure. 1.00
Screening-Detected Atrial Fibrillation and Cardiovascular Outcomes in Working-Age Adults. 0.33
Fibroblast-Specific Loss of TGF-β Signaling Mediates Lipomatous Metaplasia in the Infarcted Heart. 1.00
Role of A2AR-D2R Dimerization and D2R-Biased Signaling in PDE10A-Mediated Cardiac Hypertrophy. 1.00
TAX1BP3 Is a SUMOylated Nucleocytoplasmic Shuttling Protein and Protects Against Vascular Neointimal Hyperplasia. 0.10
Drug-Eluting Resorbable Scaffold Versus Balloon Angioplasty for Below-the-Knee Peripheral Artery Disease: 2-Year Results From the LIFE-BTK Trial. 0.76
Health Status Outcomes With Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting in ISCHEMIA 0.92
Characterization and Application of Novel Exercise Recovery Patterns That Reflect Cardiac Performance: A Substudy of the SEQUOIA-HCM Trial. 0.92
Clinical Presentation and Outcomes After Surgery for Mitral Regurgitation: Real-World Insights From the MITRACURE International Registry. 0.01
Three-Year-Follow-Up of the NOTION-2 Trial: TAVR Versus SAVR to Treat Younger Low-Risk Patients with Tricuspid or Bicuspid Aortic Stenosis. 0.04
Ivabradine in Patients Undergoing Noncardiac Surgery: a Randomized Controlled Trial. 0.06
Dapagliflozin in Patients Hospitalized for Heart Failure: Primary Results of the DAPA ACT HF-TIMI 68 Randomized Clinical Trial and Meta-Analysis of Sodium-Glucose Cotransporter-2 Inhibitors in Patients Hospitalized for Heart Failure. 0.63
Prognostic Role of Myocarditis-Like Episodes and Their Treatment in Patients With Pathogenic Desmoplakin Variants. 0.34
Transcatheter Aortic Valve Replacement With Balloon- Versus Self-Expandable Bioprostheses for the Treatment of Bicuspid Aortic Valve Stenosis 0.09
Human Single-Nucleus RNA Sequencing Identifies CD47 as a Therapeutic Target for Doxorubicin-Induced Cardiomyopathy. 1.00
TBX5 and CHD4 Coordinately Activate Atrial Cardiomyocyte Genes to Maintain Cardiac Rhythm Homeostasis. 0.90
Ponatinib, But Not the New Abl-Kinase Inhibitor Asciminib, Activates Platelets, Leukocytes, and Endothelial Cell TNF Signaling to Induce Atherosclerotic Plaque Inflammation, Myocardial Infarction, and Stroke. 1.00
Hypertriglyceridemia as a Key Contributor to Abdominal Aortic Aneurysm Development and Rupture: Insights From Genetic and Experimental Models. 0.95
Evaluation of Lipoprotein(a) as a Prognostic Marker of Extracoronary Atherosclerotic Vascular Disease Progression. 1.00
Junctophilin-2 Regulates Store-Operated Calcium Entry to Drive Cardiac Fibroblast Activation, Fibrotic Repair, and Angiogenesis After Myocardial Infarction. 1.00
The Impact of Fontan Circulatory Failure on Heart Transplant Survival: A 20-Center Retrospective Cohort Study. 0.96
New Algorithm for Estimating Left Ventricular Filling Pressure by Echocardiography. 0.47
Abelacimab Versus Rivaroxaban in Patients With Atrial Fibrillation on Antiplatelet Therapy: A Prespecified Analysis of the AZALEA-TIMI 71 Trial. 0.65
Family Screening in Relatives at Risk for Plakophilin-2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy. 0.46
Aortic Aneurysm Risk and Somatic JAK2V617FVariation: Insights From a Multicenter, Population-Based Cardiovascular Screening Study. 0.01
Burden of Cardiovascular Outcomes After SARS-CoV-2 Infection in South Korea and Japan: A Binational Population-Based Cohort Study. 0.06
4 3.80
Associations between antibiotic use and outcomes in patients hospitalized with community-acquired pneumonia and positive respiratory viral assays 0.86
Risk Assessment in a Global CVD Prevention Cohort of People with HIV by PCE, PREVENT, and SCORE2 0.95
Win Ratio Aligns With and Enhances Interpretation of REPRIEVE's Primary Findings 1.00
Target Trial Emulation of Empiric Antibiotics on Clinical Outcomes in Moderately Immunocompromised Patients Hospitalized with Pneumonia 1.00
2 1.84
Prognostic Value of Lung Injury Biomarkers in Patients Hospitalized With COVID-19 Without Respiratory Failure at Admission 0.84
Association Between Noninvasive Positive Pressure Ventilation Use and Clinical Outcomes During a Severe Asthma Exacerbation: A Cohort Study. 1.00
1 1.00
Disruption of E-cadherin in the airway led to dysplastic stressed cells and asthma-like phenotypes 1.00
7 5.73
Socioeconomic Factors and Initiation of Semaglutide or Tirzepatide Among Medicare Beneficiaries With Type 2 Diabetes. 0.86
Screening Natriuretic Peptide Levels Predicts Heart Failure and Death in Individuals With Type 1 and Type 2 Diabetes Without Known Heart Failure. 1.00
Differences in Prevalence and Incidence of Electrocardiogram Abnormalities and Cardiovascular Autonomic Neuropathy Among Randomized Glucose-Lowering Treatments in Early Type 2 Diabetes: The Glycemia Reduction Approaches in Diabetes (GRADE) Cohort. 1.00
Racial Inequity in Prescription of Semaglutide Among Eligible People With HIV 0.92
International Variation in Case Fatality After Major Coronary or Cerebrovascular Events in Individuals With Type 2 Diabetes: Evidence From ADVANCE, TECOS, and EXSCEL. 0.20
Differential Effect of GLP-1 Receptor Agonists and SGLT2 Inhibitors on Lower-Extremity Amputation Outcomes in Type 2 Diabetes: A Nationwide Retrospective Cohort Study. 1.00
Cardiovascular Outcomes and Efficacy of the PCSK9 Inhibitor Evolocumab in Individuals With Type 1 Diabetes: Insights From the FOURIER Trial. 0.75
2 2.00
A New Mouse Model for Ozone Health Effects Research 1.00
A new mouse model for ozone health effects research. 1.00
1 0.25
A longitudinal cohort study of damp and mouldy housing and children's respiratory health in Bradford, UK 0.25
6 5.50
Impacts from Sector-Specific Energy Policies on Mortality Co-Benefits and Socioeconomic Disparities Across Three Midwestern States in the Year 2050 1.00
Household Environmental Characteristics Influence House Dust Metagenome 1.00
Evaluating heterogeneity in the impact of the reformulated gasoline program on childhood and young adult lymphoma incidence: A Bayesian causal inference analysis 1.00
Stress modifies pulmonary and inflammatory response to ozone: controlled human exposure study 1.00
Toward equitable environmental exposure modeling through convergence of data, open, and citizen sciences: an example of air pollution exposure modeling amidst increasing wildfire smoke. 1.00
Impact of Ambient Ozone Exposure on Cardiac Biomarkers in Heart Failure and the Role of Sodium-glucose Cotransporter-2 Inhibitors: Findings from the TRACER-HF Trial 0.50
7 4.98
Differential Reductions in Total and Compositional PM2.5 Exposure across Socioeconomic and Demographic Groups from Emission Source Mitigation in Canada (2007–2016) 0.29
Finer Particulate Matter Exposure Disparities Exist but Vary across Pollution Concentrations 0.60
Methodological Design Choices Can Affect Air Pollution Exposure Disparity Estimates: A Case Study on California’s Agricultural Sector 1.00
Ozone Exposure (Outdoor–Indoor–Personal) and Mental Health in Young Adults 0.09
High-Resolution Assessment of Air Quality, Health, and Equity Co-Benefits of California’s 2022 Scoping Plan for Carbon Neutrality in the South Coast Air Basin 1.00
Human Health Impacts of Energy Transitions across the United States among Sociodemographic Subpopulations for the Year 2050 1.00
Marginal Asthma Prevalence from NOsubix/i/sub Emissions (MANE): A Model to Predict Pediatric Asthma Burden from Emissions of Nitrogen Oxides 1.00
55 23.13
Tetralogy of Fallot: electrophysiology-guided surgical ablation during pulmonary valve replacement 0.11
Interleukin-6 and C-reactive protein prognostic value following acute coronary syndrome 0.43
Chimeric antigen receptor T-cell therapy and cardiovascular outcomes in US Medicare beneficiaries 1.00
Obicetrapib and lipoprotein(a) levels in patients at high cardiovascular risk: a pooled analysis of trials 0.11
Angina with non-obstructive coronary arteries and myocardial bridge: long-term outcomes of surgical unroofing 1.00
Intrapericardially injected hydrogel loaded with stromal cell secretome microparticles improves post-infarction myocardial repair in pigs 1.00
Molecular mechanism leading to human coronary atherosclerosis assessed by proteomic analysis and RNA sequences 0.98
PCSK9 inhibitor treatment and outcomes in patients with atherosclerotic cardiovascular disease but without prior ischaemic events: an observational study 0.50
Stroke and systemic embolism following atrial fibrillation ablation: the EMBOL-AF Global Registry 0.03
Atrial fibrillation density as a biomarker for ischaemic stroke risk prediction 1.00
Sex differences in cardiovascular–kidney–metabolic syndrome: the FINE-HEART pooled analysis 0.38
Risk prediction in patients with heart failure with preserved ejection fraction: the LIFE-Preserved model 0.04
Prediction of incident heart failure in established atherosclerotic cardiovascular disease: the SMART2-HF model 0.06
Artificial intelligence–based quantification of breast arterial calcifications to predict cardiovascular morbidity and mortality 1.00
Laminopathies: natural history and risk prediction of heart failure 0.02
Aficamten in symptomatic obstructive hypertrophic cardiomyopathy: the FOREST-HCM long-term study 0.77
Pelacarsen and lipoprotein(a) apheresis in secondary prevention: the Lp(a)FRONTIERS APHERESIS trial 0.13
Aspirin use, lipoprotein(a), and calcific aortic valve disease: the Multi-ethnic Study of Atherosclerosis 0.94
Arrhythmias in congenitally corrected transposition of the great arteries: an international study 0.24
Frozen elephant trunk for acute type A aortic dissection: long-term outcomes over two decades 0.21
Foundation models for electrocardiogram interpretation: clinical implications 0.41
Anthracycline cardiotoxicity: role of metabolic vulnerability induced by cardiac pressure overload 0.09
Adults with Fontan circulation: prognostic value of exercise pulmonary vascular resistance index 0.63
Catecholaminergic polymorphic ventricular tachycardia mediated by ryanodine receptor 2: a validated risk stratification 0.09
Mitral transcatheter edge-to-edge repair and outcomes according to baseline health status: the RESHAPE-HF2 trial 0.21
Combined clinical, metabolomic, and polygenic scores for cardiovascular risk prediction 0.01
Sex-specific cardiac ageing and sympathetic compensation: a translational study 0.01
Osimertinib induces reversible cardiac dysfunction through the GATA4-MYLK3-MYL2 axis 0.94
Women with chronic coronary artery disease: long-term outcomes after percutaneous coronary intervention vs coronary artery bypass grafting 0.41
Artificial intelligence-enhanced electrocardiography to predict regurgitant valvular heart diseases: an international study 0.11
Genetic evaluation of early-onset atrial fibrillation: impact on patient management 1.00
Atrial cardiomyopathy: markers and outcomes 0.14
Blood pressure, plasma proteins, and cardiovascular diseases: a network Mendelian randomization and observational study 0.06
EP4/ANXA2 axis in pulmonary arterial hypertension: therapeutic implications 0.09
Drug-coated vs non-drug-coated devices for femoropopliteal artery interventions: long-term outcomes of the SAFE-PAD study 1.00
Early antiplatelet treatment for minor stroke following thrombolysis: the EAST trial 0.04
Cytosolic calcium handling signature: integration with clinical predictors enhances prediction of post-operative atrial fibrillation 0.02
Atrial fibrillation and atherosclerosis cause different vascular brain lesions on magnetic resonance imaging 0.03
C-reactive protein and cardiovascular risk among women with no standard modifiable risk factors: evaluating the ‘SMuRF-less but inflamed’ 0.80
iLIPA/i, a risk locus for coronary artery disease: decoding the variant-to-function relationship 0.94
Coronary function testing vs angiography alone to guide treatment of angina with non-obstructive coronary arteries: the ILIAS ANOCA trial 0.12
Aspirin, cardiovascular events, and major bleeding in older adults: extended follow-up of the ASPREE trial 0.29
Titin-related familial dilated cardiomyopathy: factors associated with disease onset 0.19
Low-density lipoprotein cholesterol and cardiovascular risk in the absence of calcifications on computed tomography: the Western Denmark Heart Registry 0.12
Cardiovascular benefit of continuous positive airway pressure according to high-risk obstructive sleep apnoea: a multi-trial analysis 0.60
Kidney function trajectories before and after hospitalization for heart failure with reduced ejection fraction 0.09
Excessive glycosylation drives thoracic aortic aneurysm formation through integrated stress response 0.04
ApoB and Lp(a): core measures to assess cardiovascular risk 0.17
Colchicine for secondary prevention of vascular events: a meta-analysis of trials 0.04
Radial vs femoral access for percutaneous coronary intervention: temporal trends and outcomes in the USA 1.00
Cumulative exposure to atherogenic lipoprotein particles in young adults and subsequent incident atherosclerotic cardiovascular disease 0.92
First myocardial infarction: risk factors, symptoms, and medical therapy 0.76
Immune checkpoint inhibitor-associated myocarditis: a novel risk score 0.49
A durable competitor or non-starter: is there a role for the biocompatible TiNO stent in acute coronary syndromes? 0.67
The Australian–New Zealand SCAD observational cohort study: major adverse cardiovascular events are associated with ticagrelor combined with aspirin, FMD, and history of stroke 0.67
1 1.00
Regeneration alters open chromatin and cis-regulatory landscape of erythroid precursors 1.00
3 1.98
Influenza hijacks myeloid cells to inflict type-I interferon-fueled damage in the heart 0.98
Epigenetic silencing of interleukin-10 by host-derived oxidized phospholipids supports a lethal inflammatory response to infections 0.90
A brain-to-lung signal from GABAergic neurons to ADRB2+ interstitial macrophages promotes pulmonary inflammatory responses 0.11
1 0.05
A cohort study of forced vital capacity, airway obstruction, and survival in the multinational Burden of Obstructive Lung Disease study 0.05
2 0.78
Adherence to positive airway pressure therapy and healthcare resource utilization and costs among patients with obstructive sleep apnea and obesity 0.56
Cardiovascular risk factors associated with BMI and metabolic health phenotypes based on measures of coagulation factors 0.22
9 6.93
Life Expectancy in Chronic Obstructive Pulmonary Disease. 0.95
Comparative Effectiveness and Safety of LAMA-LABA Inhalers in Chronic Obstructive Pulmonary Disease 0.75
Produce Prescription Subsidy for Patients With Diabetes 1.00
Liraglutide in Acute Minor Ischemic Stroke or High-Risk Transient Ischemic Attack With Type 2 Diabetes 0.04
Food Insecurity Interventions to Improve Blood Pressure 1.00
Mobile Integrated Health vs a Transitions of Care Coordinator for Patients Discharged After Heart Failure 1.00
Metformin and Time to Sustained Recovery in Adults With COVID-19 1.00
Early Invasive or Conservative Strategies for Older Patients With Acute Coronary Syndromes 0.20
Diseases Common in Persons With Cystic Fibrosis Among CFTR Heterozygotes 1.00
2 1.09
Global Prevalence of Hypertension in Children and Adolescents Younger Than 19 Years 0.09
Inflammatory Pathways in Residual Asthma Exacerbations Among Mepolizumab-Treated Urban Children 1.00
1 1.00
Z-Drug Use in the First Trimester of Pregnancy and Risk of Congenital Malformations 1.00
1 1.00
Temporal Trends of Common Cardiac Surgical Procedures at Veterans Affairs Medical Centers 1.00
15 10.16
Cryobiopsy vs Forceps for Bronchoscopic Lung Biopsy: The FROSTBITE-2 Randomized Clinical Trial. 0.96
Predictors of Long-Term Outcomes in Hypertrophic Cardiomyopathy 0.50
Real-World Outcomes of Transcatheter Tricuspid Valve Replacement 1.00
Cost-Effectiveness of ApoB, Non–HDL-C, and LDL-C Goals for Primary Prevention Lipid-Lowering Therapy 0.80
Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes 0.99
Donation After Circulatory Death Heart Transplant Without Preimplant Reanimation Using Rapid Ultraoxygenated Recovery 1.00
Sacubitril/Valsartan vs Enalapril in Heart Failure Due to Chagas Disease 0.03
Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia 0.42
Familial Hypercholesterolemia Screening in Childhood and Early Adulthood 1.00
Metformin to Improve Walking Performance in Lower Extremity Peripheral Artery Disease 1.00
SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria 0.38
Effects of Sodium Glucose Cotransporter 2 Inhibitors by Diabetes Status and Level of Albuminuria 0.35
Individualized Perioperative Blood Pressure Management in Patients Undergoing Major Abdominal Surgery 0.06
Impact of the MISSION Act on Quality and Outcomes of Major Cardiovascular Procedures Among Veterans 1.00
Complete AI-Enabled Echocardiography Interpretation With Multitask Deep Learning 0.67
24 19.83
The pentose phosphate pathway contributes to excess lactate production in radiation-induced fibroblast to myofibroblast transdifferentiation 1.00
Impact of salt concentration and free magnesium on human beta-cardiac myosin reveal important details about the conserved mechanochemical mechanism 1.00
Functional Evaluation of TRPC6 Missense Variants in Cancer Patients via Molecular Docking Analysis Compared with Patch Clamp Electrophysiology 0.81
Fortilin binds and stabilizes MEF2C, activates it through phosphorylation, and drives transcription of the cell structural and survival protein CTNNA3 0.71
Cell type-specific control of cardiometabolic disease by the dileucine motif of the LDL receptor-related protein LRP1 1.00
Rhinovirus Infection Promotes Suppression of Sphingosine and Enhanced Bacterial Infection in Cystic Fibrosis Airways 0.17
Divergent pathways of Surfactant Protein C maturation for disease-associated isoforms 1.00
Cantu Syndrome-Associated SUR2[H60Y] Mutation Confers Selective Gain-of-Function on Kir6.1 ATP-Sensitive Potassium Channels 1.00
Discovery of small molecule modulators of the thin filament that alter the contractile profile in a hypertrophic cardiomyopathy engineered tissue model 1.00
Thermodynamics and selection of the plasminogen activator inhibitor-1 latency transition 1.00
The histone methyltransferase MLL1 complex inhibits expression of fetal hemoglobin 1.00
MYBPC3 N-terminal missense mutations linked to hypertrophic cardiomyopathy strengthen actin binding and enhance residue mobility 1.00
Loss of O-GlcNAcylation in cardiac myocytes triggers the integrated stress response, contributing to heart 1.00
S2Tag, a novel affinity tag for the capture and immobilization of coiled-coil proteins: Application to the study of human β-cardiac myosin 1.00
Identification and rescue of congenital hyperinsulinism-associated ABCC8 mutations that impair KATP channel trafficking 0.93
Nitric oxide regulates cytochrome P450 2D6 and 3A4 activity via concentration-dependent modulation of heme loading 1.00
Gut microbiota–derived metabolite trimethylamine N-oxide alters the host epigenome through inhibition of S-adenosylhomocysteine hydrolase 1.00
Platelet Jak2 deficiency accelerates atherosclerosis with increased inflammatory response 0.06
Hemoglobin β-F41K: a recombinant oxygen carrier prototype engineered for enhanced heme retention, stability, and optimal oxygenation properties 0.22
Inflamed endothelial cells express S1PR1 inhibitor CD69 to induce vascular leak 0.91
A dual role of fibroblast–epithelial crosstalk in acute and chronic lung injury 0.08
FAK activity exacerbates disturbed flow-mediated atherosclerosis via VEGFR2-CBL-NF-κB signaling 0.94
Endothelial Protein C Receptor and Thrombomodulin Facilitate Protease-Activated Receptor 1 Cleavage at Arginine-46 by Thrombin and Activated Protein C 1.00
Redox response feature and mechanism of Arf1 and their implications for those of Ras and Rho GTPases 1.00
1 1.00
Myocardial Infarction Prior to TKA Is Associated with Increased Risk of Medical and Surgical Complications in a Time-Dependent Manner. 1.00
1 1.00
Impacts of major floods on new human respiratory health symptoms in indoor environments 1.00
1 1.00
Ovarian reserve and endothelial health in healthy reproductive-age women 1.00
25 18.08
Pulmonary Arterial Hypertension Induces a Metabolic and Inflammatory Hepatopathy 0.67
Unrestrained fatty acid oxidation triggers heart failure in mice via cardiolipin loss and mitochondrial dysfunction 1.00
Macropinocytosis inhibition attenuates profibrotic responses in lung fibroblasts and pulmonary fibrosis models 1.00
Lipoprotein(a)-Associated Proteomic Signature Predicts Cardiovascular Disease in Young Adults 0.93
Therapeutic potential of synergistic mucociliary clearance for cystic fibrosis airways by combined 𝜷-adrenergic + cholinergic agonists 0.85
Cilia-independent gas-liquid transport, a third mechanism mediating airway mucus clearance 1.00
Tet2-driven clonal hematopoiesis drives aortic aneurysm via macrophage-to-osteoclast-like differentiation 0.06
A CD57+ CD8 T cell subset links cytotoxic T cell cytotoxicity to fibrotic lung disease in systemic sclerosis 0.97
Cardiac radiotherapy-induced epigenetic memory underlies electrophysiologic and metabolic reprogramming 1.00
Carriage of rare APOB variants predisposes to severe steatotic liver disease and hepatocellular carcinoma 0.18
ADAMTS7 promotes smooth muscle foam cell expansion in atherosclerosis 1.00
Patient-Derived Xenograft Models of Fanconi Anemia-Associated Head and Neck Cancer Identify Personalized Therapeutic Strategies 0.96
DLL4+ neutrophils promote Notch1-mediated endothelial PANoptosis to exacerbate acute lung injury in sepsis 1.00
Clonal hematopoiesis activates pro-calcific pathways in macrophages and promotes aortic valve stenosis 0.30
Selective inhibition of long isoforms of phosphodiesterase 4D mitigates liver fibrosis in mouse models 0.46
A positive allosteric modulator of the β1AR with antagonist activity for catecholaminergic polymorphic ventricular tachycardia 0.71
Allergen-specific mRNA–lipid nanoparticle therapy for prevention and treatment of experimental allergy in mice 1.00
Clonal expansion of alveolar fibroblast progeny drives pulmonary fibrosis in mouse models 1.00
Myeloid-mesenchymal crosstalk drives ARG1-dependent profibrotic metabolism via ornithine in lung fibrosis 0.93
Platelet-specific SLFN14 deletion causes macrothrombocytopenia and platelet dysfunction through dysregulated megakaryocyte and platelet gene expression 0.06
Aggressive B-cell lymphomas retain ATR-dependent determinants of T-cell exclusion from the Germinal Center Dark Zone 0.13
Caloric Restriction Promotes Resolution of Atherosclerosis in Obese Mice, while Weight Regain Accelerates its Progression 0.94
Allergens abrogate antiinflammatory DNA effects and unmask macrophage-driven neutrophilic asthma via ILC2/STING/TNF-α signaling 1.00
Wilms tumor 1 impairs apoptotic clearance of fibroblasts in distal fibrotic lung lesions 0.86
PIEZO1 mediates periostin+ myofibroblast activation and pulmonary fibrosis in mice 0.09
11 4.71
Phased Variant-Supported Circulating Tumor DNA as a Prognostic Biomarker After First-Line Treatment in Large B-Cell Lymphoma: Findings From the DIRECT Study. 0.06
Prospective Validation of Circulating Tumor DNA Measurable Residual Disease After First-Line Therapy in Large B-Cell Lymphoma. 0.25
BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. 0.33
Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. 0.39
FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma. 0.38
Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial. 0.10
Mosunetuzumab plus polatuzumab vedotin in transplant-ineligible refractory/relapsed large B-cell lymphoma: primary results of the phase 3 SUNMO trial. 0.50
Remission Assessment by Circulating Tumor DNA in Large B-cell Lymphoma. 0.86
Health Outcomes Beyond Age 50 Years in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study. 0.94
Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321). 0.46
Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/TP53 Mutation: SEQUOIA Arm D Results. 0.42
1 1.00
Immune checkpoint inhibitor–induced myocarditis is dependent on CD8 T cell–derived TNF and TNFR2 signaling 1.00
4 2.90
Treatment of Pseudomonas by Removal of Cloaking Antibodies: Is Common Polysaccharide Antigen a Factor? 0.11
Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Pneumonia Hospitalization Among Medicare Beneficiaries Aged ≥65 in Long-Term Care 1.00
Inflammatory macrophages associate with tissue injury and fibrosis in a mouse model of tuberculosis 0.79
Distinct Cytokine Patterns Identify Acute and Convalescent Myocardial Involvement After Coronavirus Disease 2019: A Multicohort Biomarker Study 1.00
28 19.11
Multiscale mechanistic modelling of heterogeneity in cardiac sub‐cellular calcium handling accounting for variable t‐system density 0.33
Beat‐to‐beat variability of ventricular repolarization reveals sex‐specific instability and proarrhythmic risk 0.50
Ro5‐4864, a ligand of the mitochondrial translocator protein, protects against heart failure in mice via regulation of the p62‐Keap1‐Nrf2 axis 1.00
Sex-dependent activation of apamin-sensitive small-conductance Ca2+-activated K+ current by β1-adrenergic stimulation in rabbit ventricles 1.00
Panoramic voltage‐sensitive optical mapping of contracting hearts using cooperative multiview motion tracking with 12 cameras 1.00
Age‐ and sex‐specific modulation of human cardiac electrophysiology by doxorubicin 1.00
Intercalated disk structure, tissue heterogeneity and ion channel distribution modulate conduction and local calcium influx 1.00
Human‐derived cardiac‐neural microtissues reveal catecholaminergic polymorphic ventricular tachycardia is also a disease of the sympathetic neuron 0.05
A model of β‐adrenergic stimulation in human ventricular cells for tissue‐scale simulations of sympathetically modulated tachycardias 0.50
Selective RyR2 inhibition reduces arrhythmia susceptibility in human cardiac slices 1.00
Anti‐arrhythmic targeting of sympathetic stellate ganglion P2X3 receptors 0.18
Computational model of haemodynamics during atrial fibrillation 0.33
Evidence for acid‐sensing ion channel 3 (ASIC3) involvement in cough resulting from aspiration of gastric fluid 0.80
Structural determinants of re‐entrant drivers in atrial fibrillation: insights from digital twins derived from 3D micrometre‐resolution imaging of human heart 0.22
4D ultrasound reveals regional left atrial strain remodelling in a murine model of reversible pressure overload 0.50
APD restitution controls arrhythmia emergence in cardiac tissue with RyR2 dysfunction 1.00
Anatomical and functional mapping of vagal nociceptive sensory nerve subsets innervating the mouse lower airways by intersectional genetics 1.00
Beat‐to‐beat QT interval variability as a tool to detect the underlying cellular mechanisms of arrhythmias 1.00
Mechanistic insights into sex differences in atrial electrophysiology and arrhythmia vulnerability through sex‐specific computational models 0.90
Unveiling sex dimorphism in the healthy cardiac anatomy: Fundamental differences between male and female heart shapes 0.47
Role of baroreflex feedback loop in predictions of left ventricular growth: A multiscale finite element modelling study 1.00
Myosin‐binding protein C slows cardiac myofibril relaxation kinetics 1.00
Exercise‐induced arterial hypoxaemia in patients with heart failure with preserved ejection fraction 1.00
Computational modelling of the impact of anatomical changes on ECGs in left ventricular hypertrophy 0.06
The endogenous circadian system impairs nighttime blood pressure responses to active standing in older adults 1.00
Mechanisms underlying local Ca2+ signalling differences between right and left atrial myocytes at normal and increased frequencies 0.29
Computational modelling of the pro‐ and antiarrhythmic effects of atrial high rate‐dependent trafficking of small‐conductance calcium‐activated potassium channels 0.08
Computational modelling of cardiac fibroblast signalling reveals a key role for Ca2+ in driving atrial fibrillation‐associated fibrosis 0.89
68 54.42
Does the Genotype of Hypertrophic Cardiomyopathy Impact the Outcomes of Septal Myectomy? 1.00
Ten-year outcomes of valve-replacing versus valve-sparing aortic root replacement in Marfan syndrome patients: An observational multicenter study 0.92
Safety and Efficacy of a Dedicated Pulmonary Thromboendarterectomy Fellowship: the UK Experience at a High-Volume Center 0.10
A Prospective, Multicenter Trial of Irrigated Radiofrequency Ablation and Cryoablation to Treat Non-Paroxysmal Atrial Fibrillation 1.00
Outcomes of Adults with Congenital Heart Disease Undergoing Heart and Heart-Liver Transplantation: A Single-Center Experience 1.00
Cardiac Reoperations in Patients with Prior Thoracic Radiation: A Single-Center Analysis of Outcomes and Key Lessons 1.00
Multi-Center Comparison of Hybrid and Norwood Procedure in Patients with Fontan Circulation 0.88
25-Year Outcomes Following the Regionalization of Three Competing Pediatric Cardiac Surgery Programs 1.00
Pathology of Explanted Novel ePTFE Pulmonary Valved Conduits Reveals Paucity of Leaflet Tissue Response but Frequent Non-Adherent Thrombus Formation 1.00
Impact of Membranous Septum Length and Valve Calcification on Permanent Pacemaker Implantation After Surgical Aortic Valve Replacement 1.00
Volume–outcome relationship of mortality following surgical explant of transcatheter aortic valve replacements 1.00
Changes in ejection fraction after coronary artery bypass grafting for ischemic cardiomyopathy: Impact on survival and determinants of improvement 1.00
Risk prediction for surgery on adults with congenital heart disease: Nonprocedural clinical and social factors predominate 1.00
Mid-term outcomes after aortic valve repair with the internal geometric annuloplasty ring 1.00
The influence of reoperation on aortic arch reconstructive surgery: Evidence from a multicenter, national registry 0.17
Sodium-glucose cotransporter 2 inhibitor use and outcomes after surgical aortic valve replacement 1.00
Septal leaflet augmentation during Da Silva cone repair: Valvar function and anatomic features compared to nonpatch repair 1.00
Optimal strategy for aortic root replacement in patients of advanced age: Valve-sparing root replacement or Bio-Bentall? 1.00
Fontan pathway diameter in adults undergoing exercise catheterization: Association with hemodynamics, exercise capacity, and liver scores 0.70
Using preoperative cardiac computed tomographic conduction axis prediction to avoid damage in congenital left ventricular outflow tract and aortic valve surgery 1.00
Comparison of myocardial mechanics after mitral valve repair with leaflet preservation versus leaflet resection: A subanalysis of the randomized Canadian Mitral Research Alliance CardioLink-2 trial 0.07
Quality of life after mitral valve surgery: Results from the Cardiothoracic Surgical Trials Network 1.00
Complications following airway resections: Insights from a large contemporary multi-institutional cohort 0.21
Microinvasive, off-pump, transventricular neochordae implantation in recurrent mitral valve regurgitation after open heart surgical repair 0.02
Diastolic dysfunction persists 3 months after surgical revascularization in a large animal model of hibernating myocardium 1.00
Acute type A dissection with iliofemoral or renal malperfusion: Is frozen elephant trunk necessary? 1.00
Contemporary outcomes and health care costs associated with single-ventricle heart failure admissions in adults in the United States 1.00
Second cross-clamp in less invasive mitral valve repair for degenerative mitral regurgitation: Predictors and outcomes 0.16
Development of a patient-specific Fontan failure risk calculator using machine learning—a step toward personalized medicine 0.13
Type A aortic dissection during pregnancy and postpartum: Experience in 60 patients over 25 years 0.07
Primary biventricular repair in neonates with borderline left ventricle 1.00
Outcomes of Fontan patients undergoing combined heart-liver transplantation in pediatric hospitals across the United States 1.00
Worse Survival in Transcatheter Aortic Valve Replacement with Untreated Tricuspid Regurgitation: Implications for Surgical Intervention 1.00
Ex Vivo Heart Perfusion Offsets Ischemic Penalties with ≥6-Hour Preservation in Adult Donation-After-Brain-Death Heart Transplantation 1.00
Computational fluid dynamics-based risk stratification of modified Blalock-Taussig-Thomas shunt thrombogenicity 1.00
Association of increased red blood cell distribution width with adverse cardiorenal outcomes after cardiac surgery 0.13
Long-term outcomes of isolated tricuspid surgery in 3706 patients: Implications for the future 1.00
A surgeon's toolkit for mitral valve–induced left ventricular outflow tract obstruction with minimal septal hypertrophy 1.00
Iatrogenic aortic dissection: Insights from the International Registry of Acute Aortic Dissection 0.69
Long-Term Outcomes for Patients Undergoing Hybrid Ablation for Atrial Fibrillation 1.00
Outcomes of thoracoabdominal aortic aneurysm repair in patients with and without peripheral arterial disease 1.00
Eliminating the learning curve in robotic mitral valve repair: Results from 1400 patients 1.00
Shifting strategies to address systemic outflow tract obstruction in single ventricle anatomy with transposed great arteries 0.13
Thirty years of left atrioventricular valve reoperations following atrioventricular septal defect repair: Impact of valvar stenosis 1.00
Unplanned reinterventions after congenital cardiac surgery and hospital mortality: A report from the Pediatric Cardiac Critical Care Consortium (PC4) 0.97
Pulmonary valve repair at the time of the Ross procedure: a safe and durable strategy to address post-implantation aortic regurgitation 0.50
Metformin’s Effects Beyond Ischemia: Evaluating Cardioprotection in Non-Ischemic Myocardium in a Large Animal Model of Coronary and Metabolic Disease 1.00
Risk of Reoperation Following Rheumatic Mitral Repair: Long-term Longitudinal Analysis 0.22
Long-term Clinical Outcomes of 1020 Open Repairs of Descending Thoracic and Thoracoabdominal Aortic Aneurysms 1.00
Interpretable Artificial Intelligence to Predict Preoperative Risk Factors for Failure to Rescue after Coronary Artery Bypass Grafting 1.00
Pediatric heart transplant in donation after circulatory death using normothermic regional perfusion 1.00
Impact of Effective Orifice Area on Long-Term Survival in Bioprosthetic versus Mechanical Aortic Valves 1.00
Nanosecond Pulsed Field Ablation: Feasibility of Creating the Cox-Maze Lesion Set on the Beating Heart 0.91
Autograft Reinforcement in the Ross Procedure: A Systematic Review and Patient-level Meta-Analysis 0.20
Effect of Celsior Cold Storage on Warm Ischemia-Induced Myocardial Plasma Membrane Damage and Pyroptosis in Human Hearts from Circulatory Death Donors 1.00
Targeted immunotherapy with sphingosine-1-phosphate improves myocardial contractility and mitochondrial function in a novel murine ex vivo perfusion and transplantation model 1.00
Transcatheter Edge-to-Edge Repair versus Mitral Valve Surgery in Octogenarians: Comparative Analysis of Safety, Durability, and Survival 1.00
Ventricular Arrhythmias in Patients Undergoing Degenerative Mitral Repair: Prevalence and Impact on Survival 1.00
Challenging the Transcatheter-First Paradigm: Redo Surgical Aortic Valve Replacement After Prior Transcatheter or Surgical Aortic Valve Replacement 1.00
Five-Year Experience of Heart Transplantation Following Donation After Circulatory Death 1.00
Growth of the Fontan Pathway and its Association with Long-Term Outcomes 1.00
Outcomes Following Repair of Truncus Arteriosus with Interrupted Aortic Arch 1.00
Risk Stratification of CABG Patients Using an Artificial Intelligence ECG-Derived Age 1.00
Neo-aortic valve regurgitation and root dilation after arterial switch operation in patients with native left ventricular outflow tract obstruction 1.00
Long-term Outcomes of Semirigid Ring and Band Annuloplasty in Functional Mitral Regurgitation Patients without Advanced Left Ventricular Dilation 1.00
Impact of post-operative left bundle branch block on left ventricular remodeling following transapical beating-heart septal myectomy 0.08
Long-Term Outcomes of Patients Undergoing Multi-Arterial Grafting in Coronary Artery Bypass Grafting: Insights from a Latin American National Cohort. 0.17
Surgical Trends and Outcomes of Neonatal Ebstein’s Anomaly: Multi-Institutional Study 1.00
1 0.67
Nitrite Causes Nitrosative Stress to Iron Sulfur Clusters 0.67
84 59.09
Implications of Modest Reductions in ABI Measurements for Risk of Major Adverse Limb Events Among 223,350 Veterans 1.00
Risk-Based Nurse-Managed Personalized Heart Failure Interventions 0.94
ECG Signatures and Long-Term Ischemic Stroke Risk A Deep Learning Analysis of 200,000 Patients 0.89
Long-Term Outcomes of a Drug-Eluting Resorbable Scaffold vs Angioplasty in Infrapopliteal Chronic Limb-Threatening Ischemia 3-Year Results From the LIFE-BTK Trial 0.77
Multiarterial Grafting and Survival After Coronary Artery Bypass Grafting 0.88
Aligning Coronary Stent Trial Enrollment With the U.S. Intended-Use Population 0.95
Sudden Cardiac Death Due to Myocardial Infarction With Obstructive and Nonobstructive Coronary Arteries 1.00
Sudden Cardiac Death and its Relation to Previously Diagnosed or Occult Cardiac Disease at Autopsy 1.00
Midlife Cardiorespiratory Fitness and Healthy Aging 1.00
Body Mass Index, Clinical Outcomes, and Mortality in Heart Failure: A Mendelian Randomization Study 0.34
Sirolimus-Eluting Balloon vs Repeat Drug-Eluting Stent or Balloon Angioplasty for Coronary In-Stent Restenosis 0.78
Comparative Cardiovascular Effectiveness of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Diabetes Mellitus 0.67
Risk-Guided Atrial Fibrillation Screening With Artificial Intelligence–Enabled Electrocardiogram Models 1.00
Opportunistic Cardiovascular Risk Assessment Using Routine Head CT in the Emergency Department 1.00
Oral PCSK9 Inhibitor Enlicitide Versus Oral Nonstatin Therapies: A Phase 3 Randomized Clinical Trial 0.33
A Randomized, Placebo-Controlled Trial of Chronic Total Occlusion Percutaneous Coronary Intervention in Stable Angina - ORBITA-CTO 0.05
Automated Alerts to Improve Timely Evaluation and Treatment of Valvular Heart Disease: The ALERT Trial 1.00
Combining Genomics With Lipid and Inflammatory Biomarkers to Predict Coronary Artery Disease Risk 0.97
Use of Coronary Artery Calcium Scoring in Individuals With Elevated Lipoprotein(a) 1.00
Comparative Prognosis of Chagas and Other Cardiomyopathies 0.43
Interchangeability of the KCCQ-12 and KCCQ-23 across gt;18,000 Participants Enrolled in 4 Large-Scale Trials of Heart Failure 0.54
Single-Ventricle Disease 0.94
Use of the Ross Procedure in North America 0.46
Sotatercept in Pulmonary Arterial Hypertension 1.00
Pulsed Field Ablation vs Standard Radiofrequency Ablation for Typical Atrial Flutter: ADVANTAGE AF Trial Substudy 0.77
Public Reporting and Case Selection in Congenital Heart Surgery Signals From a Multicenter Observational Study 1.00
Association Between Age and PCI Effectiveness in Stable CAD Secondary Analysis of ORBITA-2 0.06
Enhanced Detection and Prompt Diagnosis of Atrial Fibrillation Using Apple Watch A Randomized Controlled Trial 0.05
Pulsed-Field Ablation to Enhance the Durability of Pulmonary Vein Isolation and Treat Paroxysmal Atrial Fibrillation 0.57
Hospitalizations and Mortality Among Medicare Beneficiaries at Cardiovascular Risk Disruptions and Recovery From the COVID-19 Pandemic 1.00
Natriuretic Peptide Receptor-1 Agonist for Resistant Hypertension A Randomized Phase 2 Trial 0.70
Heart Failure Quality of Care Among Asian Patients in the United States 0.86
Echocardiographic Diastolic Function Grading in HFpEF Testing the Updated 2025 ASE Criteria 0.53
Delayed Diagnosis of Transthyretin Amyloid Cardiomyopathy in the Veterans Health Administration 1.00
Association of Lp(a) With Cardiovascular Disease and All-Cause Mortality in U.S. Hispanics and Latinos 1.00
Early vs Late Staged PCI After Subintimal Tracking and Re-Entry for Chronic Total Occlusions A Randomized Trial 0.96
Trends in Prevalence, Treatment, and Control of Cardiometabolic Risk Factors Among Adults With Hypertension in the United States, 1999-2023 0.74
Trends in the Prevalence, Associated Risk Factors, and Health Burden of Heart Failure in the United States, 1988 to 2023 1.00
Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multi-Domain, Patient-Level Analysis of the MAPLE-HCM Trial 0.66
Potent P2Y12 Inhibitor Monotherapy versus DAPT after PCI in Patients With and Without STEMI: NEO-MINDSET Substudy 0.06
Proactive Management and Treatment of Aortic Stenosis: An International Expert Perspective 0.34
Incremental Value of Cardiac Myosin-Binding Protein C for the Early Diagnosis of Acute Myocardial Infarction 0.06
Follow-up Lipid Testing and Statin Initiation among Young Adults in a US Healthcare System 1.00
Association of Lipoprotein(a) and Interleukin-6 With Cardiovascular Risk MESA and UK Biobank 1.00
Multicenter Study on the Safety of Pulsed Field Ablation in Over 40,000 Patients: MANIFEST-US 1.00
Using Artificial Intelligence to Adjudicate Major Adverse Cardiovascular Events in Clinical Trials 0.88
Using Transmitral Pressure Gradients and Residual Mitral Regurgitation to Optimize Outcome After Transcatheter Edge-to-Edge Repair 0.03
Tricuspid Regurgitation Across the Spectrum of Heart Failure With Preserved Ejection Fraction 1.00
Using PREVENT Equations to Compare Intensive vs Standard Systolic Blood Pressure Control for Primary Prevention in SPRINT 1.00
Effect of Dapagliflozin on Quality of Life of Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation 0.01
Danicamtiv, a selective agonist of cardiac myosin, for dilated cardiomyopathy: A Phase 2 open-label trial 0.74
Mechanical Vacuum Aspiration and Debulking of Large Vegetations During Cardiac Implantable Electronic Device Extraction 0.94
Very High Prevalence of Nonoptimally Controlled Traditional Risk Factors at the Onset of Cardiovascular Disease 0.50
Intensive vs Conventional Intraoperative Blood Pressure Management on Cardiovascular Events After Major Abdominal Surgery The BP-CARES Randomized Trial 0.15
Trajectories of Angina After Initial Invasive vs Conservative Strategy for Chronic Coronary Disease 0.95
Artificial Intelligence Automation of Echocardiographic Measurements 1.00
Left Ventricular Health and TAVR Timing in Asymptomatic Severe Aortic Stenosis: Analysis from the EARLY TAVR Trial 0.88
Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients A Pooled Analysis 0.20
Pathogenic Cardiomyopathy-Associated Gene Variants and Prognosis in Atrial Fibrillation Results in 18,000 Clinical Trial Participants 0.69
Incidence of Heart Failure in Asian American, Native Hawaiian, and Other Pacific Islander Populations 1.00
Sex Differences in Effectiveness of Semaglutide in Patients with Peripheral Artery Disease: The STRIDE Trial 0.20
Colchicine and Longitudinal Dynamics of Clonal Hematopoiesis: An Exploratory Substudy of the LoDoCo2 Trial 0.36
Natriuretic Peptides, Body Mass Index, and Clinical Outcomes in Heart Failure with Mildly Reduced or Preserved Ejection Fraction 0.69
Effect of Vericiguat on Worsening Heart Failure in Compensated Outpatients with HFrEF: Insights from VICTOR 0.59
Effect of Aficamten Compared with Metoprolol on Echocardiographic Measures in Symptomatic Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM 0.67
Causes of Myocardial Infarction in Younger Patients Troponin-Elevation in Persons ≤65 Years Old in Olmsted County 1.00
A Polygenic Risk Score to Predict Incident Heart Failure Across the Spectrum of Cardiovascular Risk 0.98
Effects of Mavacamten on Cardiac Biomarkers in Nonobstructive Hypertrophic Cardiomyopathy Insights From the ODYSSEY-HCM Trial 0.46
Anthropometric Measures, Cardiovascular Outcomes, and Treatment Effects of Finerenone in Cardiovascular-Kidney-Metabolic Disease: Pooled Participant-Level Analysis of Three Global Trials 0.38
Echocardiographic Changes With Mavacamten in Nonobstructive Hypertrophic Cardiomyopathy Exploratory Insights From the ODYSSEY-HCM Trial 0.76
Prevalence and Predictors of Neurocognitive Dysfunction in Adults With Congenital Heart Disease Results From MINDS-ACHD 0.95
Clinical Outcomes of Conduction System Pacing vs Right Ventricular Septal Pacing in Atrioventricular Block The CSPACE Randomized Controlled Trial 0.05
Paclitaxel-Coated Balloon for the Treatment of Multilayer In-Stent Restenosis AGENT IDE Subgroup Analysis 1.00
Guideline-Directed Medical Therapy and Outcomes Among Patients With Heart Failure With Improved Ejection Fraction 0.94
Global Impact of Fixed-Dose Combination Therapies on Cardiovascular Mortality and Events, 2023-2050 A Modeling Study 0.38
AHA PREVENT Equations and Cardiovascular Disease Risk in Diverse Health Care Populations 0.98
Plaque Vulnerability and Cardiovascular Risk Factor Burden in Acute Coronary Syndrome An Optical Coherence Tomography Analysis 0.45
One-Year Results from a Multi-Center Trial of a Polymer Surgical Mitral Valve: Insights into New Technology 0.47
Differences in Arterial Events in Vascular Ehlers-Danlos, Loeys-Dietz, and Marfan Syndrome 0.58
Characterization of Arterial Aneurysms in Loeys-Dietz Syndrome 1.00
Long-Term Survival and Patient-Reported Outcomes After Staged Reconstructive Surgery for Hypoplastic Left Heart Syndrome 1.00
Predicting Heart Failure Outcomes Using Patient-Reported Health Status Real-World Validation of the KCCQ-12 1.00
Long-Acting Factor XI Inhibition and Periprocedural Bleeding An Analysis From AZALEA-TIMI 71 0.68
Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension Results of an International Multicenter Prospective Registry 0.24
6 6.00
Outcomes After Percutaneous Coronary Intervention for Chronic Coronary Disease in Adults ≥ 75 versus lt; 75 Years 1.00
Post‐Stroke Atrial Fibrillation Detection With Insertable Cardiac Monitors in Patients With Dementia and Frailty 1.00
Patterns of Oral Anticoagulant Use in Atrial Fibrillation Following Transition to Long‐Term Care 1.00
Appropriateness of Antiplatelets and Anticoagulants Among Older Adults Experiencing Falls 1.00
Emergency Department Visits for Bleeding by Adults Aged ≥ 80 Years Receiving Direct‐Acting Oral Anticoagulants 1.00
Advancing Age and Risk From the Elevated Atherogenic Index: Triglyceride (TG) to High‐Density Cholesterol (HDL‐C) Ratio 1.00
5 3.95
Acute eGFR Changes and Their Mediation of Albuminuria Reduction with Empagliflozin and Finerenone. 0.59
Association of Sphingolipids with All-Cause and Cardiovascular Death in Patients with Kidney Failure Treated with Maintenance Hemodialysis 1.00
Baseline Kidney Function, Albuminuria, and Urine Albumin-Creatinine Ratio Reduction with Finerenone, Empagliflozin, or Both: Post Hoc Analyses of CONFIDENCE Trial. 0.54
Computational Characterization of Lymphocyte Topology on Whole Slide Images of Glomerular Diseases. 0.94
Loop Diuretic Dose Intensification versus Adjuvant Thiazide for Diuretic Resistance in Acute Heart Failure: Mechanistic Randomized Controlled Trial. 0.88
6 4.90
Deployment to Karshi-Khanabad Air Base, Uzbekistan between 2001 and 2005 and subsequent risk of specific cancers among US service members 1.00
Influence of treatment, genetic predisposition, and lifestyle on cardiovascular risk factors among cancer survivors 1.00
Cardiovascular risk in long-term survivors of breast, prostate, colon, and rectal cancer 1.00
Risk of lymphoma among people with HIV in the United States, 2001-2019 1.00
Polygenic risk of coronary artery disease for long-term survivors of breast cancer 0.83
Proteogenomic and observational evidence implicate ANGPTL4 as a potential therapeutic target for colorectal cancer prevention 0.07
1 1.00
The role of C-C motif chemokine ligand 2 in the preservation of myogenic tone in the kidney microvasculature of Dahl Salt-Sensitive rats 1.00
1 1.00
Nitric oxide drives proteomic diversity through alternative splicing 1.00
1 1.00
Characterizing Integrin Tensions during Platelet Adhesion and Stiffness Sensing 1.00
5 2.01
Reduced cyclin D3 expression in erythroid cells protects against malaria 0.13
Comprehensive echocardiogram evaluation with view primed vision language AI 0.85
A neuronal architecture underlying autonomic dysreflexia 0.03
Detecting structural heart disease from electrocardiograms using AI 0.93
Imidazole propionate is a driver and therapeutic target in atherosclerosis 0.06
63 35.65
TAK1 drives inflammatory fibroblast acquisition and shapes myocardial infarction responses in male mice 1.00
Measuring multi-site pulse transit time with an AI-enabled mmWave radar 1.00
Metabolic and inflammatory biomarker trajectories after a cancer diagnosis and the risk of cardiovascular diseases 0.19
Mitochondria-derived vesicles with bioenergetic units from brown adipose tissue attenuate cardiac remodeling post-myocardial infarction 0.09
Endothelial Drp1 integrates VEGF-induced redox signaling with glycolysis through cysteine oxidation to drive angiogenesis 1.00
Gene-gene interactions between a LMNA variant and common polymorphisms drive early-onset atrial fibrillation 0.70
Joint clinical and molecular subtyping of COPD with variational autoencoders 0.91
Maternal age and pregnancy-related cardiovascular complications 1.00
Cuffless hemodynamic monitoring with physics-informed machine learning models 1.00
Chromatin rewiring of β-globin and MYC enhancers by TGF-β1 drives defective erythropoiesis 0.88
Endothelial-erythrocyte glycocalyx exchange enables liquid biopsies of endothelial function 0.05
MicroRNA-30c analog C2 decreases plasma cholesterol and atherosclerosis without causing liver injury in preclinical studies 0.97
Glycaemic variability underlies myocyte dysfunction and myocardial injury risk in diabetes 0.02
International trade and air-quality-related mortality 0.75
Hdac11 promotes idiopathic pulmonary fibrosis through macrophage M2-type polarization and myofibroblast accumulation by inhibiting Parkin-dependent mitophagy 0.07
Precision cardiovascular risk prediction in type 1 diabetes: An IMI2 SOPHIA analysis 0.08
PDK4 drives abdominal aortic aneurysm by promoting smooth muscle cell metabolic reprogramming and NLRP3-mediated pyroptosis 0.05
Osteoarthritis and analgesic consumption in haemochromatosis HFE C282Y homozygotes with normal or low iron parameters 0.06
Structural insights into single-pass transmembrane receptor GC-A activation by distinct antihypertensive antibodies 1.00
Macrophage Gsα promotes NLRP3 stability and its intervention attenuates abdominal aortic aneurysm in male mice 0.18
Single-cell multiomics uncovers an endothelial mechanosensitive PIEZO1-IL-33 axis driving pulmonary fibrosis 0.03
Vascular smooth muscle cell state trajectories mediate molecular mechanisms of coronary disease risk 1.00
Conditional BCL-2 Expression in Fibroblasts Promotes Persistent Pulmonary Fibrosis which is Reversible by Therapeutic BCL-2 Inhibition 1.00
Activation of IRF3 in cardiomyocytes impairs mitochondrial oxidative function through PGC-1α inhibition and drives heart failure 0.08
TWIST1 drives endothelial-to-mesenchymal-transition to stabilize atherosclerotic plaques 0.11
Depression of tryptophan may contribute to adverse effects of naproxen 0.96
Expert-level probabilistic breathing event detector informs phenotyping of sleep apnea 0.61
The landscape of hereditary haemochromatosis risk and diagnosis across the British Isles and Ireland 0.33
CD39 polymorphism enables lung thrombosis in sickle cell disease 1.00
Non-remnant triglyceride-rich lipoproteins due to lipoprotein lipase deficiency increase atherosclerosis in mice 0.87
Endoglin as a BMP9 co-receptor in vascular endothelial cells: prodomain displacement and TGFBRII recruitment 0.10
Single cell spatial transcriptomics integration deciphers the morphological heterogeneity of atherosclerotic carotid arteries 0.29
Integrating a host biomarker with a large language model for diagnosis of lower respiratory tract infection 1.00
Hic-5 drives epithelial mechanotransduction promoting a feed-forward cycle of bronchoconstriction 1.00
Echo-Vision-FM: a pre-training and fine-tuning framework for echocardiogram video vision foundation model 0.80
Modifiable influencing factors and their joint effects on early- and late-onset coronary heart disease 0.20
Risk factors for mortality in patients with kidney failure on hemodialysis identified by proteomic analysis of CRIC and PACE studies 0.97
Pharmacogenomics and chronotherapy of drug-induced cardioprotection in acute myocardial infarction 0.04
Regional and cell specific bioactivity of injectable extracellular matrix biomaterials in myocardial infarction 1.00
CFTR modulator therapy drives microbiome restructuring through improved host physiology in cystic fibrosis: the IMMProveCF phase IV trial 0.07
Functional genomics and tumor microenvironment analysis reveal prognostic biological subtypes in Mantle cell lymphoma 0.89
Genome-wide analysis of heart failure yields insights into disease heterogeneity and enables prognostic prediction in the Japanese population 0.26
Multi-cohort high-dimensional proteomics reveals early risk markers for lymphoid cancer subtypes 0.18
A wearable-based aging clock associates with disease and behavior 1.00
mTOR dysregulation induces IL-6 and paracrine AT2 cell senescence impeding lung repair in lymphangioleiomyomatosis 0.38
Hypertrophic cardiomyopathy mutations Y115H and E497D disrupt the folded-back state of human β-cardiac myosin allosterically 0.77
Equitable cleanup of Superfund sites leaving no U.S. community behind 0.80
Distinct cell state ecosystems for nodular lymphocyte-predominant Hodgkin lymphoma 0.85
Mepolizumab alters gene regulatory networks of nasal airway type-2 and epithelial inflammation in urban children with asthma 1.00
Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden: phase II trial 0.95
Inhibition of epithelial cell YAP-TEAD/LOX signaling attenuates pulmonary fibrosis in preclinical models 0.43
Effects of sacubitril/valsartan on hypertensive heart disease: the REVERSE-LVH randomized phase 2 trial 0.06
Integrated multiomics of pressure overload in the human heart prioritizes targets relevant to heart failure 0.97
Tumour initiated purinergic signalling promotes cardiomyocyte RBFOX1 degradation and cardiotoxicity from DNA damaging anticancer agents 0.14
Chromatin interaction maps of human arterioles reveal mechanisms for the genetic regulation of blood pressure 1.00
Cross-population GWAS and proteomics improve risk prediction and reveal mechanisms in atrial fibrillation 0.26
Immature Acta2R179C/+ smooth muscle cells cause moyamoya-like cerebrovascular lesions in mice prevented by boosting OXPHOS 1.00
Phage therapy with nebulized cocktail BX004-A for chronic infections in cystic fibrosis: a randomized first-in-human trial 0.11
Mitophagy mitigates mitochondrial fatty acid β-oxidation deficient cardiomyopathy 1.00
Imbalanced TGFβ signalling and autophagy drive erythroid priming of hematopoietic stem cells in β-thalassemia 0.11
Association between self-reported multimorbidity and longitudinal brain Aβ deposition in Alzheimer’s disease 0.88
Metabolic reprogramming of the neovascular niche promotes regenerative angiogenesis in proliferative retinopathy 0.08
Global warming may increase the burden of obstructive sleep apnea 0.07
2 1.89
Aberrant cellular communities underlying disease heterogeneity in chronic obstructive pulmonary disease 0.89
Multi-modal spatial characterization of tumor immune microenvironments identifies targetable inflammatory niches in diffuse large B cell lymphoma 1.00
22 9.86
The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial 0.14
Predicting referral need for febrile children in low-resource community settings in South and Southeast Asia 0.01
Zodasiran for cholesterol and triglyceride lowering in patients with hyperlipidemia: final report of phase 1 basket trial 0.53
Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial 0.36
The NPR1 agonist antibody XXB750 in heart failure: a phase 2 randomized trial 0.50
Liquid biopsy for the diagnosis of EBV-positive Burkitt’s lymphoma in endemic areas 0.03
Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial 0.30
Pulsed Field Conventional Thermal Ablation for Paroxysmal Atrial Fibrillation: 4-Year Outcomes in the Study 0.98
An oral, liver-restricted LXR inverse agonist for dyslipidemia: preclinical development and phase 1 trial 0.60
Fractional flow reserve-guided percutaneous coronary intervention versus medical therapy for stable coronary artery disease: long-term results of the FAME 2 trial 0.10
Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial 0.92
The NOTCH3 extracellular domain is a serum biomarker for pulmonary arterial hypertension 0.96
Anticoagulation to prevent ischemic stroke and neurocognitive impairment in atrial fibrillation: the BRAIN-AF randomized clinical trial 0.02
Global, regional, and national burden of chronic respiratory diseases and impact of the COVID-19 pandemic, 1990–2023: a Global Burden of Disease study 0.13
Endotyping-informed therapy for patients with chest pain and no obstructive coronary artery disease: a randomized trial 0.04
Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice 0.83
Antibody-mediated LOX-1 inhibition in patients with residual inflammation after myocardial infarction: a randomized phase 2 trial 0.39
AI-based diagnosis of acute aortic syndrome from noncontrast CT 0.04
Irradiation- and busulfan-free stem cell transplantation in Fanconi anemia using an anti-CD117 antibody: a phase 1b trial 1.00
Targeting the angiopoietin-like protein 3/8 complex with a monoclonal antibody in patients with mixed hyperlipidemia: a phase 1 trial 0.85
Performance of the American Heart Association’s PREVENT risk score for cardiovascular risk prediction in a multiethnic population 1.00
A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial 0.12
1 1.00
Mouse radial spoke 3 is a metabolic and regulatory hub in cilia 1.00
1 0.18
Effect of climate-driven childhood sleep erosion on potential regional economic inequality 0.18
1 0.06
NSAID use and the risk of AMD: Insights From a Multi-Center Cohort Analysis 0.06
5 4.93
Cholinergic signaling modulates intestinal pathophysiology in a drosophila model of cystic fibrosis 1.00
ASNA1 is essential for cardiac development and function by regulating tail-anchored protein stability and vesicular transport in cardiomyocytes 1.00
Anthracyclines induce global changes in cardiomyocyte chromatin accessibility that overlap with cardiovascular disease loci 1.00
Novel insights into post-myocardial infarction cardiac remodeling through algorithmic detection of cell-type composition shifts. 0.93
MYH11 rare variant augments aortic growth and induces cardiac hypertrophy and heart failure with pressure overload 1.00
3 1.46
Early aspirin withdrawal versus dual antiplatelet therapy in high-risk patients after percutaneous coronary intervention: Meta-analysis of randomized trials 0.54
Circulating gut microbial metabolites and risk of coronary heart disease: A prospective multi-stage metabolomics study 0.86
Analysis of inter-hospital transfer on clinical outcomes after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: A secondary analysis of the BRIGHT-4 trial 0.06
26 18.56
Electrical stimulation promotes longevity and regeneration in a colonial chordate 1.00
Purine metabolic adaptation protects the endothelium from disturbed flow–induced DNA damage and atherosclerosis 0.73
PPP1R3G–RIPK1–ZBP1 axis activates early-stage apoptosis and late-stage necroptosis to promote doxorubicin-induced cardiotoxicity 1.00
Single-molecule dissection of CFTR folding defects and pharmacological rescue 0.50
PARP7 protects the lung epithelial barrier from diverse environmental threats 1.00
TRIM21enhances IL-17A signaling and drives autoimmune myocarditis by promoting TRAF3 lysosomaldegradation in cardiac fibroblasts 0.08
Spatial control of myosin regulatory light chain phosphorylation modulates cardiac thick filament mechanosensing 0.70
RHOA controls oncogenic B cell receptor signaling in aggressive lymphoma 0.10
Calumenin prevents fibroblast senescence and lung aging by promoting vimentin proteostasis 0.04
Dynamic regulation of receptor-modulated endothelial NADPH oxidases 0.96
A myosin hypertrophic cardiomyopathy mutation disrupts the super-relaxed state and boosts contractility by enhanced actin attachment 1.00
Distinguishing subtypes of endothelial cells in the mouse aorta 0.20
Lipid raft proteomics identify endothelial myosin-9 (MYH9) as a regulator of low-density lipoprotein transcytosis and atherosclerosis 0.08
Platelets engage mast cells in a bilateral IL-33-driven feed-forward loop 1.00
Inequality in air pollution–attributable mortality by income level between and within countries 0.25
Soluble guanylyl cyclase, the NO receptor, drives vasorelaxation via endothelial S-nitrosation 1.00
Enhanced PIEZO1 function contributes to the pathogenesis of sickle cell disease 1.00
S-nitrosylation of pVHL regulates β2 adrenergic receptor function 1.00
3D cryoimaging of cell-mediated cholesterol crystal clearance in human atherosclerotic lesions 0.14
PD-1 expression identifies proliferating malignant CLL B cells and is a potential biomarker of response to BTK inhibitor therapy 0.83
Danicamtiv reduces myosin’s working stroke but activates the thin filament by accelerating actomyosin attachment 1.00
A FRET assay to monitor different structural states of human β-cardiac myosin including the interacting-heads motif 1.00
Remote analysis and management of sweat biomarkers using a wearable microfluidic sticker in adult cystic fibrosis patients 0.94
Wireless arm-worn bioimpedance sensor for continuous assessment of whole-body hydration 1.00
Resolving the structure and dynamics of the disordered C terminus of human cardiac troponin T and effects of cardiomyopathic mutations 1.00
The highly conserved C-terminal end segment of troponin T binds tropomyosin and actin to function in modulating contractile kinetics 1.00
7 3.66
CT Emphysema and Deep Learning-derived Vertebral Bone Loss in Individuals without COPD: Findings from MESA. 0.92
Association of CT Features with Radiologic Patterns in Interstitial Lung Disease: Multinomial Analysis in CARE-PF. 0.01
Drug-coated Balloon for Endovascular Treatment of Symptomatic Intracranial Stenotic Disease: A Multicenter Randomized Controlled Trial. 0.04
Emphysema at Baseline Low-Dose CT Lung Cancer Screening Predicts Death from Chronic Obstructive Pulmonary Disease and Cardiovascular Disease Up to 25 Years Later. 0.88
ELCAP Coronary Artery Calcium Score at Lung Cancer Screening CT Predicts Up to 25-Year Mortality. 0.67
Left-to-Right Chamber Volume Ratios at Cardiac MRI Predict Cardiac Events: A Multi-Ethnic Study of Atherosclerosis Secondary Analysis. 1.00
Right Ventricular Strain Improves Cardiac MRI-based Prognostication in Heart Failure with Preserved Ejection Fraction. 0.14
5 4.18
Severe obesity in human HFpEF alters contractile protein function and organization 1.00
Targeting modulated vascular smooth muscle cells in atherosclerosis via FAP-directed immunotherapy 0.78
Deep-learning analysis of 3D microarchitectural remodeling in hypertrophic cardiomyopathy 0.70
Preventing hypocontractility-induced fibroblast expansion alleviates dilated cardiomyopathy 0.91
Resistin-like molecule γ attacks cardiomyocyte membranes and promotes ventricular tachycardia 0.79
15 9.59
EZH2 inhibition via GSK-126 mitigates EndMT and atherosclerosis in diabetes: A translational epigenetic approach 0.05
The pleuroparenchymal fibroelastosis atlas reveals aberrant cell states and their zonation as an alternate roadmap to lung fibrosis 0.03
Cryo-EM reveals how cardiomyopathy therapeutic drugs modulate the myosin motors of the heart 1.00
Mavacamten inhibits myosin activity by stabilizing the myosin interacting-heads motif and stalling motor force generation 0.40
Regulation of sodium/calcium homeostasis by BacNav gene therapy rescues cardiac dysfunction in chronic heart failure 1.00
Design and preclinical feasibility of a pediatric heart valve stent that spontaneously adapts to growth via a spring mechanism 1.00
Structure and dynamics of a multidomain nitric oxide synthase regulated by a C2 domain 1.00
Topoisomerase III-beta protects from immune dysregulation and tumorigenesis 1.00
The mechanism of action of digoxin requires the sodium-dependent inactivation of the sodium-calcium exchanger 1.00
Metabolic reprogramming in Fanconi anemia: Evidence of compromised glucose oxidation, enhanced ketogenesis, and metabolic inflexibility 1.00
Selective AMPKβ1 activation induces fetal hemoglobin in human erythroid cells and sickle cell mice via the noncanonical NRF2 pathway 1.00
AIBP-LRP2–mediated HDL uptake restricts CXCR4+ stemlike capillary expansion and collateral circulation 0.07
How sighing regulates pulmonary surfactant structure and its role in breathing mechanics 0.29
Atopy-related immune profiles are subject to genetic influence as evaluated using school-aged twin pairs 0.19
Determining sex differences in aortic valve myofibroblast responses to drug combinations identified using a digital medicine platform 0.57
12 7.31
Sotatercept reduces bone morphogenetic protein signaling in patients with pulmonary arterial hypertension 0.09
Natural killer cell immunotherapy reverses lung fibrosis by eliminating senescent fibroblasts 0.13
Lactate transport inhibition therapeutically reprograms fibroblast metabolism in experimental pulmonary fibrosis 0.98
Diabetes-induced TREM2–endothelial cell signaling impairs ischemic vascular repair 1.00
Selective translation of ZNF281 as part of the integrated stress response system has therapeutic relevance for cardio-oncology 0.14
Extracellular BRICK1 drives heart repair after myocardial infarction in mice 0.13
Inhibition of CXCL10 and IFN-γ ameliorates myocarditis in preclinical models of SARS-CoV-2 mRNA vaccination 1.00
Dysregulated alveolar type 2 epithelial cell proteostasis promotes fibrogenic macrophage migration inhibitory factor–CD74 signaling 0.90
The IL-33 and IL-4Rα blocking antibodies itepekimab and dupilumab modulate both distinct and common inflammatory mediators in asthma 0.86
Engraftment and persistence of HBB base-edited hematopoietic stem cells in nonhuman primates 1.00
Complement is activated in patients with acute chest syndrome caused by sickle cell disease and represents a therapeutic target 1.00
Regulatory T cells attenuate chronic inflammation and cardiac fibrosis in hypertrophic cardiomyopathy 0.08
1 0.25
Developing a Population-Density-Weighted Community Health Vulnerability Index for Heat and Air Quality to Support Targeted Public Health Interventions: A Multihazard Assessment Using Remotely Sensed and Socio-economic Data in Los Angeles 0.25
3 1.27
Impact of shifting blood donation policy from gift to honour model: staggered difference-in-differences analysis in China 0.10
Continued versus discontinued oral anticoagulant treatment for unprovoked venous thromboembolism: target trial emulation 1.00
P2Y12 inhibitor or aspirin after percutaneous coronary intervention: individual patient data meta-analysis of randomised clinical trials 0.17
2 0.22
TRPML1 suppresses pulmonary fibrosis by limiting collagen and elastin deposition 0.07
A fibroblast-like endothelial cell state promotes atherosclerosis via C/EBPβ-activated TGF-β signaling 0.14
1 1.00
Microenvironmental Effects of a Non-Antibiotic Therapy for a Chronic Polymicrobial Infection Alter Microbial Physiology, Competition, and Virulence 1.00
22 16.66
Early life peanut oral immunotherapy associated with long-term ingestion and immunologic changes 1.00
Associations of rurality, child opportunity, and distance with use of pediatric asthma specialists 1.00
Predicting Asthma Prevalence Across U.S. Communities by Integrating Social Vulnerability and Environmental Risk with Machine Learning 1.00
Machine Learning Prediction of Asthma and Allergic Rhinitis in Children with Early-Onset Atopic Dermatitis 1.00
Avapritinib achieves long-term disease control with favorable safety in patients with indolent systemic mastocytosis over 3 years 0.50
Blood neutrophil genetics highlight the role of neutrophils in early childhood asthma and viral respiratory illnesses 0.03
Personal network inference identifies children at risk of recurrent wheezing and asthma 0.09
Context-specific genetic effects inform endotypes and treatment in asthma 0.88
Differential effects of subcutaneous and sublingual immunotherapy on timothy grass–specific TH2 CD4+ T-cell subsets 0.83
Club Cell RhoA Activation Amplifies Allergic Airway Inflammation by Regulating Epithelial Integrity and C1qα+ Interstitial Macrophages 0.90
Platelet-macrophage cooperation drives IL-33-dependent type 2 lung immunopathology in a sex-biased manner 1.00
Nasal gene expression shows a distinct signature in T2-high asthma but not in T2-low disease 0.04
Radical-induced Lipid Oxidation Produces a Torrent of Leukotriene-like Agonists in Severe Asthma 1.00
Cendakimab (Anti–IL-13) administration improves esophageal gene expression in eosinophilic esophagitis 1.00
The role of CC16 in the associations of preterm birth with lung function and asthma in adult life 0.41
Reduced ALDH2 in the respiratory tract associates with dysregulated alcohol metabolism and respiratory reactions in AERD 1.00
Artificial intelligence biomarker detects high-risk childhood asthma subgroup for respiratory infections and exacerbations 0.96
Genetic characterization of preschool wheeze phenotypes 0.02
Neighborhood disadvantage and the back-to-school epidemic of viral-associated asthma exacerbations 1.00
Cockroach immunotherapy modulates dominant T cell responses independent of allergen extract content 1.00
Impact of Nasal and Inhaled Corticosteroids on SARS-CoV-2 Infection Susceptibility 1.00
Single cell transcriptomic profiling of eosinophils and airway immune cells in childhood asthma 1.00
15 4.77
Angiography-derived fractional flow reserve versus coronary angiography to guide coronary artery bypass grafting in patients undergoing surgical valve procedures with concomitant coronary artery disease in China (FAVOR IV-QVAS): a multicentre, triple-blind, randomised trial 0.05
Abluminus DES+ sirolimus-eluting stent versus everolimus-eluting stent in patients with diabetes and coronary artery disease (ABILITY Diabetes Global): results from a multicentre, randomised controlled trial 0.13
Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial 0.21
Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial 0.10
Transcatheter aortic valve implantation with the Trilogy valve for symptomatic native aortic regurgitation (ALIGN-AR): a pivotal, multicentre, single-arm, investigational device exemption study 0.92
Percutaneous transcatheter valve replacement in individuals with mitral regurgitation unsuitable for surgery or transcatheter edge-to-edge repair: a prospective, multicountry, single-arm trial 0.92
Effect of evolocumab on saphenous vein graft patency after coronary artery bypass surgery (NEWTON-CABG CardioLink-5): an international, randomised, double-blind, placebo-controlled trial 0.16
Clopidogrel versus aspirin for secondary prevention of coronary artery disease: a systematic review and individual patient data meta-analysis 0.18
Benefit–harm trade-offs of intensive blood pressure control versus standard blood pressure control on cardiovascular and renal outcomes: an individual participant data analysis of randomised controlled trials 0.04
Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials 0.62
Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial 0.66
β blockers after myocardial infarction with mildly reduced ejection fraction: an individual patient data meta-analysis of randomised controlled trials 0.02
Blood pressure-lowering efficacy of antihypertensive drugs and their combinations: a systematic review and meta-analysis of randomised, double-blind, placebo-controlled trials 0.13
Collaboration on the optimal timing of anticoagulation after ischaemic stroke and atrial fibrillation: a systematic review and prospective individual participant data meta-analysis of randomised controlled trials (CATALYST) 0.13
Mitapivat in adults with non-transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE): a phase 3, international, randomised, double-blind, placebo-controlled trial 0.50
3 1.64
Combined associations of GLP-1 receptor agonists and a healthy lifestyle with cardiovascular outcomes among individuals with type 2 diabetes: a prospective cohort study 0.87
Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with homozygous familial hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trial 0.63
Effects of empagliflozin on conventional and exploratory acute and chronic kidney outcomes: an individual participant-level meta-analysis 0.15
2 1.42
Prevalence of non-communicable disease risk factors and chronic conditions among middle-aged and older adults in extreme poverty: a nationally representative cross-sectional study in India 0.75
Implications of progressive lung damage and post-tuberculosis sequelae for the health benefits of prompt tuberculosis treatment in high HIV prevalence settings: a mathematical modelling analysis 0.67
1 0.86
High-sensitivity C-reactive protein, LDL cholesterol, lipoprotein(a) and 30-year risk of stroke in healthy women: a prospective, longitudinal cohort study 0.86
1 0.05
Pirfenidone for grade 2 and grade 3 radiation-induced lung injury: a multicentre, open-label, randomised, phase 2 trial 0.05
29 16.35
In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia 0.42
Phase 3 Trials of Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis 0.82
Pulsed Field Ablation as Initial Therapy for Persistent Atrial Fibrillation 0.73
Endovascular Therapy for Post-Thrombotic Syndrome — A Randomized Trial 0.90
Multifaceted Strategies for Hypertension Control in Low-Income Patients 1.00
CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat Sickle Cell Disease 0.94
CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat β-Thalassemia 1.00
Discontinuation of Beta-Blocker Therapy after Myocardial Infarction 0.03
Mavacamten in Adolescents with Obstructive Hypertrophic Cardiomyopathy 0.75
Angiography-Derived Fractional Flow Reserve to Guide PCI 0.73
Left Atrial Appendage Closure or Anticoagulation for Atrial Fibrillation 0.87
Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis 0.44
Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism 0.03
Medical Management and Revascularization for Asymptomatic Carotid Stenosis 0.91
Beta-Blockers after Myocardial Infarction with Normal Ejection Fraction 0.02
Evolocumab in Patients without a Previous Myocardial Infarction or Stroke 0.57
Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3 0.71
Immediate or Deferred Nonculprit-Lesion PCI in Myocardial Infarction 0.02
Transcatheter or Surgical Aortic-Valve Replacement in Low-Risk Patients at 7 Years 0.83
Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis 0.64
Home-Based Care for Hypertension in Rural South Africa 0.24
Early Withdrawal of Aspirin after PCI in Acute Coronary Syndromes 0.05
Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction 0.01
Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy 0.67
Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy 0.64
Apixaban for Extended Treatment of Provoked Venous Thromboembolism 1.00
Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction 0.01
Phase 3 Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis 0.38
Rapid Recovery of Donor Hearts for Transplantation after Circulatory Death 1.00
18 12.06
Circulating CTHRC1 levels are associated with IPF disease severity and survival 1.00
Occupational inhaled exposures and risk of interstitial lung abnormalities in individuals with potential familial susceptibility to pulmonary fibrosis 1.00
Association between overuse of short-acting β2-agonists and the risk of major adverse cardiovascular events among patients with asthma 0.07
Correlates of 5-year decline in 6-min walk distance in the COPDGene cohort 0.94
Atomoxetine plus oxybutynin for obstructive sleep apnoea: a randomised-controlled trial with detailed pathophysiology 1.00
Acetazolamide to prevent ventilatory drive withdrawal in REM sleep apnoea: a randomised controlled trial 1.00
Loop gain predicts residual sleep apnoea among people using positive airway pressure 0.94
Clinical, molecular and microbial characterisation of the eosinophilic endotype of bronchiectasis: data from the EMBARC-BRIDGE study 0.09
Antifibrotic therapy and lung cancer risk in patients with idiopathic pulmonary fibrosis: a large retrospective propensity-weighted cohort study 0.50
Elastic parametric response mapping: quantitative CT scoring for local COPD severity 0.80
Disproportionate impairment in diffusing capacity predicts pulmonary hypertension with an elevated pulmonary vascular resistance in COPD 1.00
Serum IgA isotypes are associated with percent emphysema, wall thickness and lung function decline 0.97
Factors associated with guideline-concordant maintenance inhaled medication for COPD: a population-based, longitudinal cohort study 0.05
Basement membrane repair response biomarker PRO-C4 predicts progression in idiopathic pulmonary fibrosis: analysis of the PFBIO and PROFILE cohorts 0.03
Inhalational exposures associated with risk of interstitial lung disease: a systematic review and meta-analysis 0.27
Associations of interstitial lung disease subtype and CT pattern with lung function and survival 0.92
Circulating miRNAs and childhood asthma ICS response: a stratified analysis in the intervention arm of an RCT with vitamin D effect modification 0.49
Randomised, placebo-controlled trial of oral hymecromone in adults with pulmonary hypertension 1.00

Numerical information only (in the tables above) is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International.